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Résume 
Les caspases sont un groupe de protéases à cystéine qui s’activent lors de l'apoptose. Leur 
activation induit le clivage de nombreuses cibles intracellulaires, conduisant à l'activation de 
voies pro-apoptotiques et finalement au démantèlement des cellules. Cependant, des 
caspases ont été décrites dans de nombreux autres processus indépendants de l'apoptose, 
notamment dans la physiologie des cellules hématopoïétiques, des cellules musculaires, des 
cellules de la peau et des neurones. 
Comment est-ce que les cellules réconcilient-elles ces deux fonctions distinctes? Une partie 
de la réponse réside dans la nature des substrats qu'elles clivent. Certains substrats, une fois 
clivées, deviennent anti-apoptotiques. RasGAP est une cible des caspases et contient deux 
sites spécifiques de clivage par les caspases. Lorsque le niveau d’activité des caspases est 
faible le clivage de RasGAP produit un fragment N-terminal qui active un signal anti-
apoptotique, relayé par la voie de Ras/PI3K/Akt. Lorsque le niveau d’activité des caspases 
est plus élevé le fragment RasGAP N-terminal est à nouveau clivé, perdant de ce fait ses 
propriétés anti-apoptotiques.  
Dans cette étude, nous avons mis en évidence que l'activation de la voie Ras/PI3K/Akt 
induite par le fragment RasGAP N-terminal dépend de RasGAP lui-même. Par ailleurs, dans 
le but d’étudier l’importance du clivage de RasGAP dans un contexte physiologique, nous 
avons développé un modèle animal exprimant une gêne mutée de RasGAP de sorte que la 
protéine est devenu insensible a l’action de caspases. Les données préliminaires obtenues 
montrent que le clivage de RasGAP n'est pas indispensable pour le développement et 
l’homéostasie chez la souris. Finalement, nous avons développé une souris transgénique 
surexprimant le fragment de RasGAP N-terminal dans les cellules ß du pancréas. Les 
animaux obtenus ne montrent pas de symptômes dans les conditions basales bien qu’ils 
soient plus résistants au diabète induit expérimentalement. Ces résultats montrent que la 
surexpression du fragment N-terminal de RasGAP protége efficacement les cellules ß du 
pancréas de l’apoptose induite par le stress sans pourtant affecter d’autres paramètres 
physiologiques des Ilot de Langerhans. 
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Summary 
Caspases are a series of proteases that are activated during apoptosis. Their activation causes 
the cleavage of numerous intracellular targets, which leads to cell dismantling and activation 
of pro-apoptotic pathways. Caspases have been found to be involved in the physiology of 
numerous cell types including haematopoietic cells, muscle cells, skin cells and neurons. 
How cells conciliate these two opposite functions? Part of the answer lies in the nature of the 
substrates they cleave. Some substrates become anti-apoptotic once cleaved by caspases. 
RasGAP is a caspase substrate that possesses two conserved caspase-cleavage sites. At low 
caspase activity, RasGAP is first cleaved and the generated N-terminal fragment activates a 
potent anti-apoptotic signal, mediated by the Ras/PI3K/Akt pathway. At higher caspase 
activity, the N-terminal fragment is further cleaved thereby losing its anti-apoptotic 
properties.  
In the present study we show that the activation of the Ras/PI3K/Akt pathway mediated by 
RasGAP N-terminal fragment is dependent on RasGAP itself. Moreover, to study the role of 
RasGAP cleavage in a physiological model, we have developed a knock-in mouse model 
expressing a RasGAP mutant that is not cleavable by caspases. Preliminary data shows that 
RasGAP cleavage is not required for normal development and homeostasis in mice. Finally, 
we have developed a transgenic mouse model overexpressing RasGAP N-terminal fragment 
in the ß-cell of the pancreas. In basal conditions, these mice show no difference with their wt 
counterparts. However, they are protected against experimentally induced diabetes. These 
results indicate that fragment N can protect β cells from stress-induced apoptosis without 
affecting other physiological parameters of the Islets. 
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1 INTRODUCTION 
1.1 Cell death 
In the middle of the nineteenth century, soon after the discovery that organisms are 
composed of cells, cell death was found to play an important role in animal development. 
Cell death was first discovered during amphibian metamorphosis [1] and later found to occur 
in developing tissues of both vertebrates and invertebrates [2, 3]. In 1969 Lockshin coined 
the expression Programmed Cell Death (PCD) after observing that cell death occurred at 
predictable times and places during development [4]. In 1972, after a detailed analysis of 
morphological evidence, Kerr and colleagues proposed to distinguish between cells dying 
after acute lesions and cells dying during animal development or tissue homeostasis. In the 
first case, cells tend to swell and rupture, inducing inflammation, in a process called 
necrosis. By contrast, cells dying during development or tissue homeostasis shrink and 
condense keeping their integrity, in a process named by Kerr and colleagues Apoptosis 
(from the Greek apoptōsis (αποπτωσισ) ‘falling off’ of petals from a flower, or leaves from 
a tree) [5]. Robert Horvitz and colleagues used Caenorhabditis Elegans as a model organism 
and 20 years later discovered that all cells have an in-built suicide program and started to 
characterize its building blocks (reviewed in [6]). 
Ever since, cell death has typically been discussed as either apoptosis or necrosis. The 
finding that other forms of cell death are also programmed is gradually changing this notion, 
figure 1. According to a recent classification, eight different types of cell death were 
delineated [7], and some researchers describe as many as 11 pathways of cell death in 
mammals, 10 of which appear to be programmed [8]. These pathways can be broadly 
divided into two main groups: apoptotic and non-apoptotic. 
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Apoptotic cell death is biochemically defined as a form of programmed cell death executed 
by the activation of the caspase cascade. Non-apoptotic cell death includes autophagy, 
necrosis (sometimes called oncosis), mitotic cell death (mitotic catastrophe) and caspase 
independent cell death (CICD). 
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1.1.1 Apoptotic cell death. 
Apoptotic cell death comprises apoptosis, which will be discussed later, and anoikis.  
Anoikis is a form of apoptosis induced by loss of attachment to the surrounding extracellular 
matrix or to other cells. Besides its specific form of induction, the molecular mechanisms 
appear to be classic apoptosis. Resistance to anoikis seems to be an important step in the 
development of cancer [9]. 
1.1.2 Non-apoptotic cell death. 
Autophagy is based on an evolutionary conserved and genetically controlled turnover of 
cellular constituents that occurs in all eukaryotic cells [10]. This process is activated in 
response to nutrient starvation, during differentiation, and following developmental triggers. 
It is an adaptive process responding to metabolic stress that results in degradation of 
intracellular proteins and organelles [11]. 
Mitotic catastrophe occurs during or shortly after a dysregulated or failed mitosis and can be 
accompanied by morphological alterations such as micronuclei (which often are 
chromosomes or chromosome fragments that have not been distributed evenly between the 
daugther nuclei) and multinucleation (the presence of two or more nuclei with similar or 
heterogeneous sizes, resulting from deficient separation during cytokinesis) [7]. 
Necrosis/Oncosis is usually a consequence of pathophysiological conditions such as 
infection, inflammation or ischemia. The prominent features are cellular energy depletion, 
damage to membrane lipids with cell membrane swelling and rupture, loss of function of 
homeostatic ion pumps/channels, and activation of non-apoptotic proteases [11]. Although 
necrosis has been considered to be a passive process, some recent findings suggest it could 
be a regulated process [12-14]. 
Caspase-independent cell death shares features with classical apoptosis (e.g., mitochondrial 
outher membrane permeabilization (MOMP) induction, diffusion of some proteins from the 
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intermembrane space of the mitochondria and DNA fragmentation). As it does not rely on 
activation of the caspase cascade, it is therefore classified as a non-apoptotic form of death 
[15]. 
1.2 Apoptosis 
According to the Nomenclature Committee on Cell Death, apoptosis is a type of cell death 
that is accompanied by rounding-up of the cell, retraction of pseudopodes, reduction of 
cellular volume (pyknosis), condensation of the chromatin, fragmentation of the nucleus 
(karyorhexis), little or no ultrastructural modification of cytoplasmic organelles, plasma 
membrane blebbing, and maintenance of an intact plasma membrane until late stages of the 
process [7]. The biochemical hallmark of apoptosis is the activation of a series of zymogenic 
cystein proteases that cut after aspartic residues, the caspases. 
Apoptosis is involved in the normal physiology, including elimination of damaged or virally 
infected cells, negative selection in the thymus and during development, elimination of 
temporary structures and tissue remodelling (e.g. bud limb development). A careful control 
of cell death mechanisms is fundamental. Aberrant activation may contribute to different 
diseases (e.g. neurodegenerative disorders, AIDS, ischemic injury, etc). In contrast, deficient 
cell death is a major factor in the aetiology of cancer and autoimmune disorders, among 
others [16]. 
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1.2.1 Physiological apoptosis. 
In the human body about one hundred thousand cells are produced every second by mitosis 
and a similar number dies by apoptosis to maintain homeostasis and for specific tasks such 
as the regulation of immune cell selection and activity [17]. Most cells produced during 
embryonic development undergo programmed cell death before the end of the perinatal 
period. Some of the more important physiological processes, in which apoptosis is involved, 
are described below, figure 2. 
1.2.1.1 Development and Morphogenesis 
During development many cells are produced in excess which eventually undergo 
programmed cell death and thereby contribute to sculpturing many organs and tissues [18]. 
A good example of this process is the formation of free and independent digits by massive 
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cell death in the interdigital mesenchymal tissue [19-21]. Furthermore, during the 
development of the brain, half of the neurons that are initially created die in later stages 
when the adult brain is formed [22]. 
A classic example of morphogenesis is seen in amphibian tadpoles, where an increase in 
thyroid hormone in the blood induces cells in the tail to undergo programmed cell death, 
facilitating the resorption of the developing tail [23]. 
Programmed cell death also occurs wherever epithelial sheets invaginate and pinch off to 
form tubes or vesicles, as in the formation of the vertebrate neural tube or lens, and it is 
observed when two epithelial sheets come together and fuse, as in the formation of the 
mammalian palate [2]. 
1.2.1.2 Homeostasis. 
A paradigm of apoptosis involvement in maintaining homeostasis is the immune system. 
The majority of the developing lymphocytes die either during genetic rearrangement events 
during formation of the antigen receptor, during negative selection or in the periphery, 
thereby tightly controlling the pool of highly efficient and functional but not self-reactive 
immune cells and at the same time keeping lymphocyte numbers relatively constant [24].  
1.2.2 Apoptosis in disease. 
Involvement of apoptosis in development of disease can be due to both decreased or 
increased cell death. 
Diseases characterized by the accumulation of cells include cancer, autoimmune diseases, 
and certain viral illnesses. Cell accumulation can result from either increased proliferation or 
the failure of cells to undergo apoptosis in response to appropriate stimuli. Even if 
involvement of increased cell proliferation in these disorders has been investigated, 
increasing evidence suggests that failure to undergo apoptosis, rather than increased 
proliferation, is involved in these diseases. 
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1.2.2.1 Cancer 
Failure to complete apoptosis is a hallmark of cancer and the main target for anticancer 
therapies. Survival of neoplasic cells beyond their normally intended lifespan requires to 
overcome the need for exogenous survival factors, to acquire resistance to the necessity of 
cell-cell contacts [9] and to provide protection from hypoxia and oxidative stress as the 
tumor mass expands [25, 26]. Similarly, tumours are resistant to apoptosis induced by DNA 
damage or abnormal chromosomal segregation. These apoptosis defects permit survival of 
genetically unstable cells, providing opportunities for selection of progressively more 
aggressive clones [27]. In this context, it is not surprising that p53, commonly named “the 
guardian of the genome” [28], is mutated in the majority of human tumours and is often 
associated with advance tumor stage and poor patient prognosis [29] 
Several members of the Inhibitor of Apoptosis Proteins family have been involved in 
apoptosis. For example, survivin is prominently expressed in most cancers [30] and XIAP 
overexpression is a negative prognosis marker in acute myelogenous leukaemia (ALM) [31]. 
1.2.2.2 Autoimmunity 
Autoimmune diseases can be due to the failure to remove autoimmune cells that arise during 
development or that develop because of somatic mutation during an immune response. 
Inadequate clearance of apoptotic cells has been linked to autoimmune and persistent 
inflammatory diseases [32]. Defective removal of apoptotic cells by macrophages leads to 
secondary necrosis, release of danger signals and engulfment by dendritic cells. Uptake of 
apoptotic cells by dendritic cells can lead to autoimmunity because protein cleavage in dying 
cells can lead to the generation of neo-autoantigens [33]. Patients suffering from systemic 
lupus erythematosus might have some uncharacterized defects in the ability of macrophages 
to eliminate apoptotic cells [34]. 
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1.2.2.3 Viral infection. 
A number of viruses have developed strategies to disrupt normal regulation of cell death 
within the infected cell. For example, the first member of the IAP family has been found in 
baculorivus [35]. Viral homologues of cellular FLICE-inhibitory protein (cFLIP), known as 
viral FLIPs (vFLIPs), are contained in several poxvirus and herpes virus genomes. vFLIP 
seems to inhibit caspase-8 activation by binding to it and FADD and thus inhibiting the 
formation of the death-inducing signalling complex (DISC)[36-38]. 
1.2.2.4 AIDS 
AIDS is generated by the infection of the human immunodeficiency virus (HIV) and is 
correlated with apoptosis-mediated depletion of CD4+ T cells [39, 40]. Expression of the 
viral envelope gp120-gp41 complex in infected cells mediates onset of apoptosis of both 
infected and non-infected cells. Thus, chronically HIV-infected cells can serve as effector 
cells to induce apoptosis in uninfected target CD4+ T cells [41, 42]. 
1.2.2.5 Neurodegenerative disorders. 
Wide variety of neurodegenerative disorders are characterized by the loss of a specific 
population of neurons [43] (e.g. Alzheimer's disease, Parkinson's disease, amyotrophic 
lateral sclerosis (ALS), retinitis pigmentosa, spinal muscular atrophy, etc). 
1.2.2.6 Diabetes. 
Excess of apoptosis has been linked to the pathophysiology of both, type 1 and type 2 
diabetes. While in type 1 diabetes ß-cell death is caused by autoimmune attack of both CD4+ 
and CD8+ lymphocytes [44], in type 2 diabetes apoptosis is induced as a result of 
hyperglycemia [45], hyperlipidemia [46, 47] and the presence of inflammatory cytokines 
[48]. 
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1.2.3 Mechanism of Apoptosis 
Apoptosis is characterized by the activation of numerous proteins in a temporally as well as 
spatially tightly regulated sequence. Initiation is induced by two main stimuli: the binding of 
ligands to cell surface receptors of the tumor necrosis factor receptor (TNFR) superfamily 
that activates the “extrinsic pathway” and the damage of DNA integrity by various stress 
factors, radiation or major changes of the homeostasis of cells that initiate the “intrinsic 
pathway”, figure 3. 
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1.2.3.1 Extrinsic pathway. 
The extrinsic pathway, which leads to caspase activation, is initiated by oligomerization of 
“death receptors” triggered by the binding of their ligand. Death receptors belong to the 
tumor necrosis factor receptor (TNFR) superfamily, which includes TNFR-1, Fas/CD95 and 
the TNF-related apoptosis-inducing ligand (TRAIL) receptors DR-4 and DR-5 [49]. All 
members of the TNFR family are characterised by an extracellular cysteine rich domain 
(CRD), responsible for ligand recognition and oligomerization [50]. Subsequent signalling, 
induced by the oligomerization, is mediated by the intracellular death domains (DD). 
The oligomerization of the “death receptors”, induced by the binding of their ligands, leads 
to recruitment of adaptor proteins and to the formation of the death-inducing signalling 
complex (DISC). Fas-associated death-domain protein (FADD), one of these adaptor 
proteins, interacts with the death receptors via its own DD and recruits caspase-8 by binding 
to its death effector domain (DED). In addition to the initiator caspases, the DISC may 
contain other adaptor and signalling proteins, such as TNF-receptor associated death domain 
(TRADD), receptor interacting protein (RIP) and RIP-associated Ich-1/CED-3 homologous 
protein with a death domain (RAIDD). Furthermore, a set of inhibitory proteins, named 
FLICE-inhibitory proteins (FLIPs), is known to interact with the DISC. FLIPs contain two 
DED that interact with the DED of FADD and thus inhibit caspase-8 recruitment and 
activation by the TNFR family members [51, 52].  
Recruitment of caspase-8 to the DISC domain is believed to trigger its activation; even tough 
it is not yet clear whether it is dimerization or autocatalytic cleavage the responsible for pro-
caspase activation [53]. Once activated, caspase-8 cleaves downstream effector caspases 
resulting in cell death. Cells able to directly induce apoptosis upon death receptor 
stimulation, are known as type 1 cells [54]. In contrast, in type 2 cells, receptor stimulation is 
not sufficient to induce apoptosis. In these cells, the mithocondrial pathway amplifies the 
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signal. This is achieved via caspase-8 mediated cleavage of Bcl-2 family member Bid. When 
Bid is cleaved, its truncated form, tBid, translocates to the mitochondria and together with 
Bax and Bak induces the release of cytochrome c (Cyt c) and other pro-apoptotic proteins to 
the cytosol [55]. 
 
1.2.3.2 Intrinsic pathway. 
The intrinsic pathway is mediated by the mitochondria and it is responsible for triggering 
apoptosis in response to cellular stress signals. The critical event that triggers apoptosis by 
the intrinsic pathway is the release of Cyt c and other mitochondrial proteins mediated by 
mitochondrial outer membrane permeabilization (MOMP). 
Upon apoptotic stimuli, Cyt c is released into the cytosol where, in the presence of ATP, it 
mediates the allosteric activation and hepta-oligomerization of the adaptor molecule 
apoptosis-protease activating factor 1 (Apaf-1), generating the complex known as 
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apoptosome, figure 5. Each apoptosome can recruit seven dimers of caspase-9 and promote 
their activation leading to proteolytic self-processing. 
For a long time, the release of Cyt c has been postulated to be an “all-or-nothing” process. 
Now cumulative data suggest that Cyt c release is rather biphasic. Accordingly, a first wave 
of Cyt c release would affect only a small part of the Cyt c pool. The release of this first pool 
of Cyt c then boosts several different amplification loops, which allow for the complete 
release of Cyt c. This biphasic Cyt c release adds another layer of regulation for the 
apoptosis triggering. The release of a small part of the mitochondrial pool of Cyt c would 
prevent the triggering of apoptosis upon an accidental Cyt c release. 
Other proteins released from the mitochondria, together with Cyt c, facilitate apoptosis 
induction by preventing IAP-mediated caspase inhibition. Good examples are the second 
mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with 
low isoelectric point (Smac/DIABLO) and high temperature requirement protein A2 (HtrA2, 
also known as Omi) that interact and neutralize inhibitor of apoptosis proteins (IAPs) when 
released into the cytosol [56, 57]. Another set of proteins released from the mitochondria are 
the flavoprotein apoptosis-inducing factor (AIF) and endonuclease G (Endo G) which are 
mainly involved in caspase-independent cell death [58]. 
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Bcl-2 family. 
MOMP is a highly controlled process regulated by the members of the Bcl-2 family. Bcl-2, 
the founding member of the family, was discovered at the chromosomal breakpoint of 
translocation t(14;18) bearing human B-cell lymphomas [59, 60]. The Bcl-2 family has 
expanded significantly and includes both anti- and pro-apoptotic molecules. Members of this 
family have the ability to form homo- as well as heterodimers, suggesting neutralizing 
competition between these proteins. It seems that the ratio between pro- and anti-apoptotic 
subsets helps to determine partially the susceptibility of cells to a death signal [61]. 
Bcl-2 family members are characterized by the presence of up to four Bcl-2 homology (BH) 
domains, denominated BH1, BH2, BH3 and BH4, figure 6 [62-64]. Anti-apoptotic members 
of the Bcl-2 family (Bcl-2, Bcl-xl, A1, Bcl-w, Mcl-1) show sequence conservation in the 
four BH domains and are initially located at the level of the outer mithocondrial membrane, 
where they bind and inhibit pro-apoptotic proteins of the Bcl-2 family [65]. They are also 
found at the level of the endoplasmic reticulum, or nuclear membrane [66-68]. Anti-
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apoptotic Bcl-2 family members act by preventing MOMP, and thus inhibit Cyt c release 
and Apaf-1 activation, figure 6.  
Bcl-2 pro-apoptotic family members can be separated in two structurally different 
subfamilies. The multidomain pro-apoptotic Bcl-2 family is structurally similar to the anti-
apoptotic members of the family and shares three of the four BH domains (BH1-3). Bax, 
Bak and Bok are notable members of this family. In normal conditions they are located in 
the cytosol but upon apoptotic stimuli they suffer a conformational change and are 
translocated and inserted into the mitochondria outer membrane. They seem to be necessary 
[69] and sufficient [70] to induce mitochondrial permeabilization. The BH3-only pro-
apoptotic Bcl-2 family members (Puma, Noxa, Bim, Bid, Bad, Bnip3, etc) are structurally 
heterogenous and share only the BH3 domain with other Bcl-2 family members and 
therefore are named BH3-only proteins. BH3-only proteins act upstream of multidomain 
pro-apoptotic Bcl-2 family members. They operate as sensors for death stimuli in the cell, 
and play a major role in transducing signals from the cytosol to the mitochondria. BH3-only 
proteins can promote apoptosis by two different mechanisms: some BH3-only proteins 
preferentially interact with anti-apoptotic Bcl-2 family members, dissociating them from 
Bcl-2 pro-apoptotic family members, which in turn promote apoptosis; others act through 
direct activation of Bak and Bax [65]. 
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1.3 Caspases 
Caspases are an evolutionarily conserved family of aspartate specific cystein-dependent 
proteases (Cysteine ASPartate-specific proteASES) [71] with central functions in apoptotic 
and inflammatory signalling pathways. Caspases and their homologues have been reported 
in species that range from Caenorhabditis elegans [72], Drosophila Melanogaster [73] and 
even Saccharomyces cerevisiae [74], figure 7. Fourteen caspases have been described until 
now (caspases 1-14), twelve of which are present in humans (caspases 1–10, caspase 12 and 
caspase 14). Caspase 11 was identified as the mouse homolog of human caspase 4, while 
caspase 13 has been shown to be the bovine homolog of human caspase 4 [75]. 
Caspases can be grouped according to their function. The first group, implicated in the 
maturation of cytokines, includes caspases 1, 4, 5 and 14 [76]. The involvement of this 
group of caspases in the process of apoptosis is not straightforward. The second group, 
which includes caspases 2, 3, 6, 7, 8, 9, 10 and 12, is implicated in apoptosis. 
Caspases involved in apoptosis are divided into initiator and executioner caspases. The 
initiator caspases, which include caspases 2, 8, 9, 10 and 12, have long prodomains with 
recognisable homotypic protein–protein interaction motifs, such as the death effector domain 
(DED) or the caspase recruitment domain (CARD) that contribute to the transduction of 
various signals into proteolytic activity. The two major initiator caspases, 8 and 9, function 
through distinct pathways, which culminate in the activation of the main effector pro-
caspase 3 in the cytosol. Caspases 3, 6 and 7 are known as the effector caspases. The 
zymogens of these caspases have short prodomains and lack intrinsic enzymatic activity. 
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1.3.1 Activation. 
In contrast to the reversible nature of the kinase action, the result of protease activity is 
irreversible. Therefore, the activity of proteases has to be tightly controlled. In the case of 
caspases, they are synthesized in the form of inactive zymogens and they dependend on a 
complex machinery for their activation.  
Initiator caspases lay at the top of the caspase activation cascade, and therefore there is no 
upstream protease to activate them. As the activation of the caspase cascade depends upon 
their activation, they need to be sensitive to activation signals, but they do not have to be 
activated irreversibly. This requisite is needed to avoid that their accidental activation 
triggers rapid cell death. In contrast to what was originally thought, apical or initator 
caspases are not activated by cleavage, but rather by dimerization [77]. This dimerization-
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driven activation occurs in the context of large supramolecular complexes that act as sensors 
for death signals. 
In the case of the extrinsic pathway, the binding of a death signal to a death receptor triggers 
the clustering and recruitment of adaptor proteins as well as procaspase-8. Almost ten years 
ago the Induced-Proximity Model for the activation of caspase-8 was proposed [78]. In this 
model, the formation of the death-inducing signalling complex (DISC) brings procaspase-8 
molecules in close proximity so that they can cleave each other. This model has now evolved 
and in the current model, named proximity-induced dimerization, dimerization rather than 
cleavage, triggers caspase-8 activation [77]. 
In the case of the intrinsic pathway, the apoptosome plays the role of a receptor of 
intracellular death signals and as for the case of caspase-8 and the DISC, caspase-9 is 
activated by dimerization, mediated by the formation of the apoptosome [79]. This is 
confirmed by the fact that processed caspase-9 was found to be catalytically inactive [80]. In 
contrast, dimers were highly active [80]. 
The dimerization-induced activation of apical caspases contains in itself a safeguard 
mechanism. If the apoptotic stimulus is short (incomplete Cyt c release or a short death-
receptor activation) initiator caspases will not be irreversibly committed to the activation of 
executioners caspases, and could in turn activate other physiological processes. 
Executioner caspases are in turn activated through a proteolytic cascade set out by the 
initiator caspases [53], resulting in a cleavage that generates a large and small subunits [81]. 
Because their activation is irreversible, the activity of executioner caspases needs to be 
tightly regulated. This is achieved by a family of proteins called Inhibitor of Apoptosis 
Proteins (IAPs). First discovered in baculovirus [35], mammalian orthologs were 
subsequently found [82, 83]. IAPs are characterized by the presence of one to three copies of 
the Baculovirus IAP repeat (BIR) and a RING domain (a zinc binding motif). The best-
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characterized IAP is X-linked IAP (XIAP) [84, 85], which is a very potent anti-apoptotic 
molecule due to its capacity to directly inhibit caspases. IAPs activity is not restricted to 
apoptosis regulation. Survivin, an IAP family member that possesses one BIR repeat and 
lacks the RING domain, is involved in cell cycle regulation [86]. 
 
The effector caspases are responsible for cleaving most of the known apoptotic substrates, 
such as the DNA fragmentation factor 45 (DFF 45), poly- (ADP-ribose) polymerase 
(PARP), ACINUS (apoptotic chromatin condensation inducer in the nucleus) and lamin 
[87], all of which characterize nuclear apoptosis. Other caspase substrates have different 
locations within the cell and are involved in many cellular functions. Disruption of their 
functions by caspases ensures both inhibition of basic cell functions that could inhibit 
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apoptosis [81] and the formation of the apoptotic bodies. These last structures are recognised 
and eliminated by neighbour and/or immune cells [88]. 
1.3.2 Substrates. 
Caspases do not degrade other proteins; they cleave targets at one of a few highly selective 
sites. Even though caspases cleave some structural proteins, they more frequently target 
signalling proteins and thus modulate specific downstream pathways, which in turn execute 
cell death. Therefore, caspases serve as signalling mediators that orchestrate a complex 
network of downstream execution pathways. 
Caspase substrates can be divided into six major categories [81]:  
I. Proteins directly involved in the regulation of apoptosis. 
The most obvious example of the cleavage of a protein involved in apoptosis is the cleavage 
of executioner caspases by initiator caspases. Other examples of pro-apoptotic proteins 
activated by caspase cleavage are Bid [55, 89] and ICAD (inhibitor of caspase-activated 
DNAse) [90, 91] which plays a critical role in the internucleosomal DNA degradation 
characteristic of apoptosis [92]. Anti-apoptotic molecules such as Bcl-2, [93] Bcl-XL [94] 
and XIAP [95] are inactivated by caspase cleavage. 
II. Proteins mediating/regulating apoptosis signal transduction. 
A number of anti-apoptotic protein kinases are rendered inactive by caspase cleavage. Akt, a 
known pro-survival factor, is cleaved following matrix detachment in epithelial cells [96, 
97]. RIP kinase, the survival-signalling component associated to the DISC complex, is also 
cleaved by caspase 8 causing its inactivation [98, 99]. On the other hand, pro-apoptotic 
kinases are activated by caspase cleavage. Fas signalling results in caspase-3-mediated 
cleavage of PAK2 (p21-activated kinase 2), which contributes to the formation of apoptotic 
bodies [100]. Another kinase activated during genotoxic stress and Fas-induced apoptosis is 
MEKK1 [101, 102]. 
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III. Structural and essential function proteins.  
In addition to the activation of different apoptotic pathways, caspases contribute to the 
dismantling of the cell. For example, cleavage of gelsolin [103] and fodrin [104] leads to 
disruption of the actin filament network and contributes to cells rounding up and detaching 
from the matrix during apoptosis. Nuclear fragmentation critically depends on the disruption 
of the nuclear filamentous network through the cleavage of lamins A, B1 and C by caspases 
[105, 106]. 
IV. Proteins required for cellular repair. 
Failure to repair or restore cellular functions in response to cellular distress is one of the 
main triggers of apoptosis. DNA-dependent protein kinase (DNA-PK), which play a critical 
role in the induction of DNA repair in response to double-strand breaks [107], is one of the 
upstream caspase targets during apoptosis [33, 108]. Another protein involved in DNA 
repair, poly(ADP-ribose) polymerase (PARP) (widely used experimentally as an apoptosis 
marker) is also cleaved during apoptosis [109]. 
V. Proteins regulating cell cycle 
Induction of apoptosis appears to coincide with the activation of multiple cell cycle 
associated factor through cleavage and inactivation of their inhibitors (wee1, p21CIP1 and 
p27KIP1 [110, 111]). 
VI. Proteins involved in human pathologies. 
Caspases may be involved in the direct cleavage of disease-associated factors. Two of the 
most striking examples are Huntington disease and Alzheimer’s disease. In Huntington 
disease, caspases may contribute to the generation of expanded polyQ fragment on 
huntingtin through cleavage in the cluster of DXXD sites [112, 113]. In Alzheimer’s disease, 
caspase 3 has been found to cleave the cytosolic tail of the amyloid precursor protein (APP) 
[114]. 
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As mentioned, the great majority of caspase substrates are involved in the promotion of 
apoptosis when cleaved. There are, however, exceptions to this rule. A small part of the 
caspase substrates acquires new anti-apoptotic properties when cleaved by caspases. For 
example, cleavage of PKCε activates the enzyme and this seems to generate an anti-
apoptotic signal [115]. Triggering of the B-cell receptor induces the cleavage by caspases of 
Lyn and Fyn [116, 117] into fragments that inhibit apoptosis. The p54 Lyn fragment may 
favour cell survival by modulating c-myc levels [117]. The survival pathways activated after 
the cleavage of Fyn or PKCε have not been characterized. Moreover, the ability to regulate 
apoptosis in cells specifically lacking the capacity of cleaving Fyn, Lyn, or PKCε has not 
been evaluated yet. Low levels of caspase activity provoke the cleavage of RasGAP [118] 
and its N-terminal fragment induces the activation of the Ras/PI3K/Akt antiapoptotic 
pathway [119]. 
1.4 RasGAP 
RasGAP is a cytosolic protein involved in the regulation of Ras and Rho signalling pathways 
[120-122] and necessary for normal cell mobility [123].  
1.4.1 Ras. 
Ras proteins have defined a group of 20-25 kDa guanine nucleotide-binding proteins that 
share structural homology, the superfamily of Ras-related proteins. The Ras proteins were 
the first oncogene to be described. First discovered as the transforming genes of the Harvey 
and Kirsten murine sarcoma viruses [124], subsequently they were found in the eukaryotic 
genome [125-127]. 
Mammalian cells encode three functional ras genes: H-Ras, K-Ras and N-Ras, which show a 
very similar structure and function. The protein product of each vertebrate Ras gene is 
approximately 21 kD in size, containing 188 amino acids. 
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Ras proteins act as molecular switches. According to the structures of small G proteins, they 
have two interconvertible forms: GDP-bound inactive and GTP-bound active forms [128-
130], figure 9. Ras affinity for GDP is higher than for GTP and its intrinsic GTPase activity 
is extremely low. Without the assistance of “facilitator” proteins Ras would be constitutively 
locked in the inactive state [131]. Son of Sevenless (Sos) acts as a nucleotide exchange 
factor (GEF); upon binding to Ras, Sos facilitates the release of the tightly bound GDP and 
its replacement by GTP. On the other hand, GTPase activating proteins (GAPs) activate Ras 
GTPase activity by up to 105 folds [132, 133], by directly interacting with Ras [134]. 
Therefore, GAPs and GEFs act in concert to keep Ras activity in check. 
Ras controls the activity of multiple effectors [135]. The protein kinase c-Raf was the first 
effector to be discovered [136] and is so far the most studied one. Ras binding to c-Raf leads 
to its activation and initiation of the MEK-ERK signalling pathway. Another well 
established Ras effectors are the catalytic subunit of PI3K [137] and the Ral guanine 
nucleotide dissociation stimulator (RalGDS) [138, 139]. 
1.4.2 RasGAP 
p120RasGAP, a key regulator in the Ras signalling pathway [120-122], was the first GAP to 
be characterized at a molecular level [140, 141]. It was first described as a cytosolic protein 
fraction able to stimulate hydrolysis of Ras-bound GTP [141]. Rasa1, encodes for two 
different isoforms: p100 and p120 [132]. The expression of p100 is restricted to the primate 
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placenta. In mammals, p120 is expressed ubiquitously, although there is a great amount of 
variability between organs. Disruption of RasGAP gene (Rasa1) leads to embryonic lethality 
at day 10.5 due to aberrant cardiovascular development [142]. 
p120 RasGAP is active on Ha-Ras, Ki-Ras, N-Ras, and R-Ras, but not on Rho/Rac/Rab 
proteins [128, 140, 141]. To date at least seven different GAPs have been found in 
mammals: p120RasGAP, the neurofibromatosis type 1 protein NF1 [143], GAP1m, 
GAP1IP4BP[144], IQGAP1 [145], SynGAP (a Ras GAP selectively expressed at excitatory 
synapses in the brain [146]) and CAPRI which is calcium dependent [147]. 
 
The C-terminal part of RasGAP contains the GTPase activating domain (GAP), responsible 
for GTP hydrolysis. This domain is highly conserved, both among the different forms of Ras 
GAPs and between species. Interestingly the N-terminal region contains several domains 
susceptible to be involved in interaction with other proteins (Figure 10): 
• C2 domain: is involved in binding phospholipids in a calcium dependent manner or 
calcium independent manner 
• PH domain: consist of approximately 120 amino acids that binds with high affinity to 
specific phosphoinositides such as phosphatidyl-inositol (PI)-4,5-bisphosphate, PI-
3,4-P2 or PI-3,4,5-P3. 
• SH2 (Src homology 2) domain: is a domain of approximately 100 amino acids that 
binds to specific phospho (pY)-containing peptide motifs. 
• SH3 (Src homology 3) domain: it generally binds to Pro-rich peptides. 
• Proline-rich modules interact with SH3 domains. 
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All these RasGAP functional domains specify different ways of interacting with numbers of 
signalling proteins [148]. A non exhaustive list of proteins that can associate with the SH3 
domain flanked with two SH2 domains include a number of tyrosine kinase receptors 
(Platelet derived growth factor receptor [149] and Insulin growth factor receptor [150]), v-
Src, p62Dok and p190RhoGAP [151-153]. 
1.4.2.1 RasGAP as a possible effector of Ras. 
RasGAP is usually described as a negative regulator or Ras. In cells expressing an oncogenic 
form of Ras, RasGAP is no longer able to negatively regulate Ras. However, in these cells 
RasGAP has been described to act as a Ras effector, in functions related with cells 
proliferation, differentiation and apoptosis, independently of its GAP activity.  
I. The opening of the muscarinic receptor-activated potassium channel was inhibited 
by the Ras-RasGAP complex. This inhibition was found to rely on RasGAP SH2-SH3 
domains [129, 154, 155]). 
II. The microinjection of an antibody directed at RasGAP SH3 domain in Xenopus 
oocytes blocked H-Ras-induced germinal vesicle breakdown and blocked the Ras-mediated 
activation of cdc2 kinase [156-158]. 
III. A RasGAP mutant, lacking the Ras binding domain, inhibited the activity of 
oncogenic Ras, when targeted to the plasma membrane, without affecting the action of 
normal Ras [159]. 
IV.  RasGAP modulate cell adhesion and cytoskeleton [160] through its interaction with 
p190RhoGAP in a Ras-independent manner [161]. Accordingly, overexpression of 
p120GAP impairs the chemotactic response of fibroblasts to PDGF and lysophosphatidic 
acid [162]. 
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V. RasGAP interacts, in a Ras independent manner, with G3BP, a protein showing 
similarity to RNA binding proteins and which has been proposed to affect both the stability 
and translation efficiency of mRNAs [163]. 
1.4.2.2 RasGAP is a caspase substrate. 
RasGAP is a caspase substrate [122, 164] that bears two distinct caspase-3 consensus 
cleavage sites that are sequentially targeted by the caspases as their activity increases [118].  
The first consensus site, located at position 455, is cleaved at caspase activity that are hardly 
detectable and more importantly that do not induce apoptosis. The cleavage at position 157 
only occurs at higher caspase activity and requires that the first cleavage had already taken 
place [118], suggesting that the first cleavage induces structural modifications that allow the 
second cleavage to take place. 
The first caspase cleavage generates two fragments. The C-terminal fragment consists of the 
GAP, C2 and PH domains while the N-terminal domain contains the SH2-SH3-SH2 tandem 
and the proline rich domain. Surprisingly, when overexpressed, RasGAP N-terminal 
fragment induces a potent anti-apoptotic signal, mediated via the Ras/Phosphatidylinositol 3-
Kinase/Akt pathway [119]. This protective pathway occurs independently of NFκB activity, 
since fragment N blocks the activation of the NFκB pathway [119]. Activation of this 
pathway seems to be crucial for cell survival in low-stress conditions [10]. At higher caspase 
activity, RasGAP N-terminal fragment is further processed by caspases at position 157 
generating two smaller fragments named N1 and N2. This cleavage abrogates fragment N 
mediated anti-apoptotic signalling, allowing the apoptotic pathway to proceed. Interestingly, 
fragment N2 when overexpressed in cancer cells potentiate the pro-apoptotic effect of 
genotoxins in a p53-dependent manner [118, 165]. 
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1.5 Aim of the work. 
We have previously shown that when RasGAP is cleaved it induces a potent antiapoptotic 
signal and particularly that cells unable to generate fragment N are extremely sensitive to 
low stress conditions [10]. 
The aim of this work was to understand the physiological role played by the cleavage of 
RasGAP by the caspases. Therefore, the following projects were developed. 
1. Characterization of how fragment-N mediates Ras/PI3K/akt pathway activation. 
2. Generation and characterization of knock-in mice expressing a mutant form of 
RasGAP that cannot be cleaved by caspases (RasGAP (D455A)). 
3. Generation and characterization of transgenic mice expressing fragment-N in the ß-
cells of the pancreas, to study its protective effect in the context of diabetes. 
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2 RASGAP IS INVOLVED IN THE ANTIAPOPTOTIC RESPONSE OF 
ITS CLEAVAGE FRAGMENTS. 
2.1 Introduction. 
Apoptosis is a vital phenomenon that participates in the elimination of infected, damaged or 
unnecessary cells. The elimination of those cells is essential for normal development and 
homeostasis in multicellular organism. Every cell is programmed to undergo apoptosis in 
response to the appropriate stimulus (e.g. growth factor withdrawal, DNA damage, oxidative 
stress and stimulation of death receptors). Cells undergoing apoptosis exhibit characteristics 
morphological and biochemical transformations including nuclear condensation, cell blebbing, 
DNA cleavage, abrogation of anti-apoptotic pathways, formation of apoptotic cell bodies 
and expression of apoptotic markers at the cell surface [1]. 
The ultimate responsible for the dismantling of cell undergoing apoptosis is a specific subset 
of cysteine-dependent proteases that cut after aspartic residues, named caspases [2]. 
Caspases exert their apoptotic function by cleaving many different kinds of proteins like 
structural proteins (e.g. fodrin [3]), other caspases (e.g. caspases 7/9), tumour suppressors 
(e.g. Retinoblastoma [4]), nucleases (e.g. ICAD [5]) and pro-apoptotic proteins (e.g. Bid 
[6]). 
Until recently, the activation of caspases was considered a point of no return; once cells had 
activated their caspases they were irremediably committed to die [2]. Accordingly, most 
caspase substrates when cleaved become pro-apoptotic, like Bid or become pro-apoptotic 
by losing their anti-apoptotic effects [7]. 
This view has been contested with the recent discovery that apoptotic caspases have 
additional functions besides being the executioners of cell death. For example, caspase-3 has 
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been involved in lymphocyte proliferation [8] and muscle differentiation [9]. How cells deal 
with low levels of caspase activity without fully activating the cell death pathway? Part of 
the answer is now known: a small part of the caspases substrates acquires new anti-
apoptotic properties when cleaved by caspases; this is the case for the protein kinases Fyn 
[10] and Lyn [11], although the biochemical mechanism has not being described yet.  
The p120 Ras GTPase activating protein (RasGAP) a key regulator in the Ras signalling 
pathway [12-14] is a atypical caspase substrate [15]. RasGAP possesses 2 distinct caspase 
cleavage sites, located at aminoacids 157 and 455 [15]. At low caspase activity RasGAP is 
cleaved at its 455 site, and the N-terminal generated fragment induces an anti-apoptotic signal 
that is mediated via the activation of the Ras-PI3K-Akt pathway [16]. When caspase 
activity increases the N-terminal fragment is further cleaved at its 157 site abrogating its anti-
apoptotic activity [15]. 
RasGAP in addition to its GTPase activating domain contains, in the N-terminal part, one 
SH3 domain flanked by two SH2 domains, a plekstrin homology domain (PH), a calcium 
dependent lipid binding domain (C2) and a proline rich domain.  All these domains specify 
different ways for RasGAP to interact with the plasma membrane and other proteins.  
Confirming this, RasGAP has been reported to interact with many different proteins. 
Interestingly, RasGAP in addition of its role as a negative regulator of Ras, has been found to 
be a possible effector of Ras [17]. Accordingly, the role of RasGAP in the survival pathway 
mediated by its cleavage fragment was investigated. 
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2.2 Results 
2.2.1 RasGAP is involved in the anti-apoptotic pathway activated by its cleavage 
fragments. 
The detailed mechanism by which fragment N activates Ras and Akt is currently unknown. 
To assess the role played by full-length RasGAP in the activation of this pathway, mouse 
embryonic fibroblast (MEFs) derived from mice expressing the wild-type form of RasGAP 
(RasGAP+/+ MEFs) or RasGAP knock-out (RasGAP-/- MEFs) were infected with 
lentiviruses coding for fragment N or empty lentiviruses as a control. The activation of Akt 
was then assessed. As it can be seen in Figure 1A, Akt is activated by fragment N only in 
cells expressing full-length RasGAP. To determine if the lack of Akt stimulation by fragment 
N in RasGAP knock-out cells was specifically due to the absence of RasGAP, a rescue 
experiment was performed. RasGAP-/- MEFs were infected with an empty virus or a 
lentivirus encoding an HA-tagged form of RasGAP. Additionally, the cells were co-infected 
or not with a lentivirus expressing fragment N (Figure 1B). Figure 1 B shows that only in the 
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presence of RasGAP were RasGAP-/- MEFs able to support fragment N-induced Akt 
activation. Infection with lentiviruses (especially when two different viruses were used) led 
to some processing of the ectopically expressed RasGAP protein into fragment N (see lanes 
3 and 5 in Figure 1B), which is an indication that viral infection exerts a stress on the cells 
[2]. However, when the cells were infected with either RasGAP- or fragment N-encoding 
lentiviruses together with an empty virus, no activation of Akt was detected (Figure 1B, 
lanes 4 and 5). This indicates that the very low levels of fragment N that were generated from 
the expressed RasGAP protein were not sufficient to activate Akt.  
2.2.2 RasGAP cleavage is not the trigger for Akt activation. 
The results described above indicate that full-length RasGAP is required for fragment N-
induced Akt stimulation. As RasGAP can be cleaved into various fragments by caspases [3], 
it could be envisioned that RasGAP fragments rather than the full-length protein were 
required for fragment N to activate Akt. Mutation of the cleavage recognition site at position 
455 completely prevents RasGAP from being processed by caspases [2, 3]. When RasGAP -
/- MEFs were infected with the uncleavable form of RasGAP (RasGAP D455A), fragment N 
was still able to induce Akt phosphorylation (Figure 2A). This indicates that processing of 
RasGAP is not required to allow fragment N-induced Akt stimulation. 
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2.2.3 The GTPase-activating domain of RasGAP is required but not sufficient to 
allow fragment N-induced Akt activation. 
RasGAP bears multiple domains, including SH and PH domains and a GTPase-activating 
domain. To assess if the function of the latter was important to allow fragment N-induced 
Akt stimulation, a mutant form of RasGAP in which arginine 789 is mutated into an alanine 
residue was generated (RasGAPR789A). Arginine 789 of RasGAP favors Ras-mediated GTP 
hydrolysis and its mutation is expected to hamper the GTPase-activating function of 
RasGAP [18]. RasGAP-/- MEFs infected with a lentivirus encoding RasGAPR789A did not 
support fragment N-induced Akt phosphorylation (Figure 2A). This suggests that the GAP 
activity of RasGAP is required for fragment N to activate Akt. We next assessed if the GAP 
activity was sufficient for fragment N-mediated Akt stimulation. Initially, we wanted to test 
a construct bearing only the GAP domain of RasGAP. However, this construct was very 
poorly expressed in cells. We therefore generated a slightly longer construct consisting of 
the C2 domain and the GAP domain of RasGAP (C2-GAP). When RasGAP-/- MEFs were 
infected with lentiviruses encoding C2-GAP and fragment N, no Akt phosphorylation was 
detected (Figure 2C). These results indicate that the GAP activity of full-length RasGAP is 
required but not sufficient for fragment N-mediated Akt activation. 
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2.2.4 Fragment N does not interact with RasGAP. 
Recent data on the structure of the SH3 domain of RasGAP (amino acids 281–341) suggests 
that this domain can form dimers [19]. This raises the possibility that RasGAP and fragment 
N, which both bear the SH3 domain, could form homo- or hetero-dimers. Immuno-
precipitation experiment were performed to assess if RasGAP can interact with fragment N. 
HEK 293T cells were transfected with an HA-tagged forms of fragment N together with a 
GFP-tagged version of RasGAP. An HA-tagged form of RhoGAP was used as positive 
control due to its known ability to bind RasGAP [20]. Figure 4A shows that, in conditions 
where interaction between RasGAP-GFP and RhoGAP can readily be detected, no binding 
of RasGAP to its fragment N was observed. This was not due to an intrinsic inability of 
fragment N to interact with proteins because fragment N could interact with RhoGAP and be 
co-immuno-precipitated (Figure 3B). These results suggest that fragment N does not bind to 
its parental molecule. 
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2.2.5 Fragment N does not interact with Akt. 
Earlier results have indicated that fragment N leads to Akt activation in a Ras-dependent 
manner [16]. However, there has been a claim that fragment N directly binds Akt, leading to 
a Ras-independent activation of the kinase [21]. We therefore assessed whether we could 
detect an interaction between fragment N and Akt. As seen in figure 4, whilst the immuno-
precipitation of RhoGAP brings down fragment N, immuno-precipitation of Akt did not, 
despite larger immuno-precipitated amounts of Akt compared to RhoGAP. It appears 
therefore unlikely that the way fragment N activates Akt can be attributed to a direct 
interactions of the two proteins. 
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2.3 Discussion. 
In addition to modulate Ras activity and to be a potential effector of Ras [22], RasGAP plays 
a role in the regulation of apoptosis [23]. The first cleavage of RasGAP by caspases allows 
the cells to maintain a low level of caspase activity while avoiding the cells to engage 
themselves in apoptosis [23]. The anti-apoptotic signaling generated by RasGAP cleavage is 
mediated by the N-terminal fragment (fragment N) that activates the Ras-PI3K-Akt pathway 
[16]. Cells unable to cleave RasGAP are very sensitive to different stresses [23] 
demonstrating the important function of RasGAP cleavage in cell survival. 
RasGAP has been shown to be required for some Ras-mediated cellular responses [24-27]. 
The N-terminal part of RasGAP has in fact been shown to activate Ras and, subsequently, 
PI3K and Akt [16]. However, how fragment N stimulates the Ras-PI3K-Akt pathway is not 
understood. Here we show that fragment N cannot act independently of its parental molecule 
RasGAP to activate the pathway leading to Akt stimulation. This suggests that besides its 
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well known inhibitory action on Ras via its GAP domain, RasGAP in concert with its 
fragment N participate in the activation of the Ras-PI3K-Akt pathway. However, we could 
not detect any physical interaction between RasGAP and fragment N, which suggests that 
the mechanisms by which RasGAP and its fragment regulate Ras pathways are complex and 
probably involve other molecules. 
2.4 Materials and Methods. 
2.4.1 Cell culture and transfection. 
The RasGAP +/+ mouse embryonic fibroblasts (MEFs; clone 12.78), the RasGAP -/- MEFs 
(clone 12.64) [23], and HEK 293T cells were maintained in DMEM containing 10% 
newborn calf serum (Invitrogen, cat. no. 26010-074) at 37°C and 5% CO2. Transfections 
were performed using the calcium phosphate DNA precipitation method [28], and DNA 
amounts were normalized using pcDNA3 vector. 
2.4.2 Plasmids. 
The plasmid bearing the uncleavable form of fragment N (N-D157A.lti) used for the 
production of fragment N-encoding lentivirus has been described previously [23]. Plasmid 
HA-GAP.dn3 encodes the full-length human RasGAP protein bearing an HA tag 
(MGYPYDVPDYAS) at the amino-terminal end [15]. Plasmid HA-D455A.dn3 encodes a 
RasGAP mutant that cannot be cleaved at position 455 [15]. HA-GAPN.dn3 encodes the 
HA-tagged (at the N terminus) version of RasGAP fragments from positions 1 to 455 [15].. 
Plasmid HA-RasGAP (no 3’ UTR).lti, used for the production of lentiviruses encoding full-
length RasGAP without the 3’ UTR was described previously [29]. HA-RhoGAP.dn3 is a 
generous gift from Jeffrey Settleman. HA-RasGAP (R789A).dn3 was generated by PCR 
mutagenesis [30] using the following primers: 
ATGAAGCCACTACCCTATTTGCAGCCACAACACTTGCAAGCAC, 
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TACCTAGCATGAACAGATTGAGGGGCAAACAACAGATG, 
TACCTAGCATGAACAGATTG and CTCATGCAAGGGAAGGGCAA. HA-C2-GAP.dn3 
was generated by PCR amplification of plasmid HA-RasGAP (no 3’ UTR).dn3 with primers 
sense 
GGGGATCCGCCACCATGGGCTACCCGTACGACGTGCCGGACTACGCTTCTACAT
CCAATAAACGCCTTCGT and antisense GGGACCCTGGTTCAATACCT; a 369 bps 
BamHI/BlpI PCR fragment was ligated to a 6460 bps BamHI/BlpI from HA-RasGAP (no 3’ 
UTR).dn3, to generate the HA-C2-GAP.dn3 plasmid. All of the constructs containing PCR 
inserts have been sequenced to verify that no PCR errors occurred. 
2.4.3 Chemicals 
Hexadimethrine bromide (Sigma, Polybrene, cat. no. 52495) 
Alexa Fluor 680-conjugated anti-rabbit antibody (Molecular Probes, Eugene, OR; cat. no. 
A21109) or an IRDye 800-conjugated anti-mouse antibody (Rockland, Gilbertsville, PA; 
cat. no. 610-132-121) 
2.4.4 Western Blot 
Cells were lysed in monoQ-c buffer (70 mM ß-glycerophosphate, 0.5% Triton X-100, 2 mM 
MgCl2, 1 mM EGTA, 100 mM Na3VO4, 1 mM dithiothreitol, 20 mg of aprotinin per ml) 
Western blotting was performed as described previously [31] using a homemade ECL 
reagent [15] or the infrared imaging system (LICOR Biosciences, Bad Homburg, Germany 
[29].  
2.4.5 Lentiviral Infection 
Recombinant lentivirus was produced as described previously [32]. Briefly, 293T cells were 
cotransfected using the calcium phosphate DNA precipitation method [28] with 10 µg of the 
lentiviral vector containing the cDNA of interest (e.g., N-D157A.lti), 2.5 µg of the envelope 
protein-coding plasmid (pMD.G), and 7.5 µg of the packaging construct (pCMV∆R8.91). 
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Two days after the transfection, the virus-containing medium was harvested. To determine 
how much of the virus preparation was needed to infect 100% of the MEFs, subconfluent 
wild-type MEFs seeded in six-well plates were cultured overnight with various volumes of 
fragment N or RasGAP encoding recombinant virus. After removal of the virus solution, the 
cells were maintained for two more days before fixation and immunocytochemical staining 
with antibodies directed at the protein expressed by the lentivirus. The lowest volumes of the 
lentiviral preparations required to infect 100% of the cells were chosen for further 
experiments. 
Infection of the cells was performed as follows. Hexadimethrine bromide was added to cells 
cultured in six-well plates to a final concentration of 5 µg/ml, followed by the addition of the 
lentiviruses. The plates were then centrifuged 45 min at 800 xg and placed 24 h at 37°C in a 
5% CO2 humidified atmosphere. The medium was then replaced with fresh medium, and the 
cells were further cultured for an additional 48-h period before being used in specific 
experiments. 
2.4.6 Immunoprecipitation.  
HEK 293T cells (2x106) were plated in a 10 cm petri dish and transfected with plasmids 
encoding the appropriate constructs. Twenty-four hours after the transfection, the cells were 
lysed in RIPA buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 0.25 % Na-Deoxycholate, 1 
% NP40, 1 mM EGTA, 1 mM NaF, 0.5 mM Na3VO4 and protease inhibitor). One milligram 
of total cellular protein was precleared with protein G sepharose for 15' at 4°C. The 
precleared lysate was then incubated with an anti-HA antibody for 2 hr at 4°C. After two 
hours, protein G sepharose beads were added and incubated for a further hour in identical 
conditions. The beads were then washed 3 times and the proteins released using 60 µl of 2x 
sample buffer at 95°C. The samples were loaded on a 10 % polyacrilamide gel, blotted onto 
nitrocelulose membrane and analyzed by Western blot. 
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3 IMPORTANCE OF RASGAP CLEAVAGE IN MOUSE PHYSIOLOGY. 
3.1 Introduction 
Caspases are known as the executioners of apoptotic cell death [1]. Once cell are subjected to 
an apoptotic stimulus, upstream or initiator caspases (e.g. caspase 8 and 9) are activated, and 
in turn cleave and activate downstream or executioner caspases (e.g. caspase 3 and 7) [2]. 
Once activated, executioner caspases cleave a plethora of proteins resulting in the stimulation 
of pro-apoptotic pathways and the inactivation of pro-survival pathways, eventually leading 
to the physical dismantling of the cell [3, 4]. 
It was earlier assumed that caspase activation would inexorably lead to apoptotic cell death 
[1]. Even though this remains true in most situations, there is increasing evidence linking 
caspase activation and physiological functions other than apoptosis. For example, caspase 3 
is required for skeletal muscle [5] and neural stem cell development [6]. Moreover, caspase 8 
is required for lymphocyte activation and homeostasis [7, 8]. 
The involvement of caspases in non-lethal responses implies that the pro-death functions of 
the caspases are kept in check in these particular cases. Cells have developed several anti-
apoptotic mechanisms to ensure cell survival involving proteins of the Bcl2 family and 
members of the inhibitor of apoptosis (IAP) family [9-11]. There is however a major 
difference between these two types of proteins. While the anti-apoptotic Bcl2 family 
members prevent the activation of caspases, the IAPs can, directly or indirectly, inhibit 
caspase activity [12]. 
As mentioned above, the great majority of caspase substrates, when cleaved, participate in 
the apoptotic process. There are however some exceptions. Cleavage of PKCε activates the 
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enzyme and this in turn mediates the activation of antiapoptotic signals [13]. Activation of 
B-cell receptor triggers the cleavage of the kinases Fyn and Lyn generating fragments that 
inhibit apoptosis [14, 15]. In addition, we have shown that RasGAP, a regulator of Ras and 
Rho signalling pathways, when cleaved by caspases generates a potent anti-apoptotic 
response [16]. 
RasGAP possesses two conserved caspase-3 cleavage sites [16]. At low levels of caspase 
activity, RasGAP is first cleaved at position 455. The N-terminal fragment (fragment N) 
generated by the cleavage activates a potent anti-apoptotic-signalling pathway mediated by 
the Ras/PI3K/Akt pathway [17], which is crucial for cell survival in low stress conditions 
[18]. However, at higher caspase activity, fragment N is further cleaved at position 157 and 
this abrogates its anti-apoptotic activity [19]. This has led us to postulate that RasGAP acts 
as a sensor of caspase activity to control a death/survival switch [20]. At low levels of 
caspase activity (i.e. levels that would be required for the non-apoptotic functions of 
caspases), RasGAP is cleaved once into fragment N to protect cells from fully activating 
their executioner caspases. When caspase activity increases, fragment N is further cleaved 
and inactivated, allowing the full caspase activation and apoptosis induction. 
In the present work, we present the characterization of the first animal model, in which a 
caspase substrate involved in anti-apoptotic signalling, has been rendered caspase resistant. 
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3.2 Results 
3.2.1 Generation of a knock-in mouse expressing a caspase insensitive mutant of 
RasGAP. 
The introduction of a mutation into the RasGAP genomic sequence was made by 
homologous recombination. The targeting strategy consisted in replacing RasGAP exon 10 
by a mutant form carrying the mutation (Figure 1A). The targeting vector (described in 
material and methods) contained a mutant version of exon 10 in which the D455A mutation 
was introduced together with a silent mutation to introduce a restriction site (Figure 1C). The 
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presence of the targeted allele was visualized by southern blot (Figure 1B) or by PCR 
followed by NgoMIV digestion (Figure 1C). Additionally, the presence of the mutation in 
mice homozygous for the mutated allele (RasGAPD455A/D455A mice) was assessed by Western 
blot of protein extracts of macrophages from wild-type mice of from RasGAPD455A/D455A 
mice treated with increasing concentrations of cisplatin. Even though fragment N could not 
be detected in macrophages, fragment N2, which can only be generated from fragment N 
[16], was only detected in wild-type macrophages (Figure 1D). 
 
The mutated and wild-type alleles segregated following the expected Mendelian ratios 
among the offsprings obtained after breeding RasGAP+/D455A mice (Table 1). Furthermore, 
fertility and longevity were not affected in the knock-in mice. In addition, histology of six 
month-old RasGAPD455A/D455A mice was apparently identical to wild-type littermates 
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(supplementary Figures S1-4). This indicates that preventing RasGAP cleavage does not 
affect development and homeostasis of the mice. 
3.2.2 Apoptosis sensitivity. 
We have previously demonstrated that cell lines lacking the capacity to generate fragment N 
were more sensitive to stress-induced apoptosis compared to their wild-type counterparts 
[18]. As expected, MEFs derived from RasGAPD455A/D455A mice treated with increasing 
concentrations of cisplatin showed increased levels of apoptosis when compared to the wild-
type-derived counterparts (Figure 2A). Surprisingly when primary macrophages where 
treated with cisplatin they did no exhibit a different in apoptotic levels. When treated with 
UV macrophages showed balanced results. RasGAPD455A/D455A macrophages apoptosis levels 
where consistently higher that their wt counterparts, but the differences were not always 
significant. When treated with staurosporine RasGAPD455A/D455A macrophages were clearly 
more sensitive when compared to wt macrophages. 
If different cells types showed increased sensitivity towards apoptosis we hypothesized that 
if treated chronically with an apoptotic stimulus, RasGAPD455A/D455A mice should decrease 
survival rate than the wt mice. The results obtained (data not shown) were contradictory, 
indicating that probably the absence of fragment N was not detrimental for mice survival, 
probably due to the presence of redundant mechanisms that could cope with the cisplatin-
induced stress. 
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3.2.3 RasGAP and the immune system. 
Caspases have been involved in the development and homeostasis of the haematopoietic 
system. In order to determine if the immune system development was affected, different 
haematopietic precursor and their development was followed in the bone marrow, spleen and 
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thymus. As shown in figure 3A, none of these lineages seems to be affected, and the 
remaining differences can be attributed to inter-individual differences. 
Caspase activity has also been involved in T-cell proliferation. To establish whether 
RasGAP cleavage play a role, T-cell activation induced proliferation was assessed. As 
shown in figure 3B, splenocytes derived from RasGAPD455A/D455A mice, showed a decreased 
proliferative rate, as measured by MTT. The MTT assay being by no means specific these 
results should be confirmed using other more specific methods to establish if the increased 
proliferation is due to T-cell proliferation and not to the proliferation of another cell type 
present in the splenocyte population. Furthermore, the decreased proliferation measured by 
MTT could be due to both, increased proliferation of wt cell or increased apoptosis in the 
RasGAPD455A/D455A cells. All these parameters should be assessed in order to establish the 
veracity of these findings. 
 
3.2.4 Role of RasGAP in the regulation of chronic stress in cardiomyocites. 
To study the effect of RasGAP cleavage in a model of chronic stress, RasGAPD455A/D455A and 
RasGAPwt/wt were left untreated of subjected to transaortic constriction (TAC) to induce a 
pressure overload in the heart. The increase in pressure in turn induces cardiac hypertrophy. 
After performing the TACs, heart evolution was followed by ecography and a series of 
parameters (showed in figure 4) were measured. Mice were measured at 2, 4 and 6 weeks 
post TAC. Figure 4 show the results obtained at 6 weeks post TAC. Even though no 
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difference showed to be significative, some parameters showed a clear tendency with p 
values very close to the threshold of significance. These parameters show a tendency for a 
higher level of hypertrophy in RasGAPD455A/D455A mice, with an increased HW/BW ratio and 
an increased left ventricular mass, figure 4.  
 
3.3 Discussion 
The results obtained so far demonstrate that RasGAP cleavage is not indispensable for 
normal development and homeostasis in mice. As shown in Figure 1, the RasGAP D455A 
mutation was successfully introduced into the genome of the mice. The southern blot shows 
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that the recombination was successful and Figure 1C clearly shows that the mutation is 
effectively present in the genome of mice bearing the targeted allele. At the protein level, the 
presence of the mutation is clear in the absence of fragment N2 in macrophages derived from 
RasGAPD455A/D455A mice. Even though only fragment-N2 is visible in macrophages derived 
from RasGAPwt/wt, as fragment-N2 is generated by the cleavage of RasGAP at both caspase-
cleavage sites (see Figure 11 in chapter 1), the presence of fragment N2 is an indirect probe 
of impossibility of fragment-N generation. 
We have previously shown that cells expressing a caspase-insensitive RasGAP mutant were 
rendered more sensitive to low stress conditions, caused by the impossibility of cells to 
cleave RasGAP and induce the associated cell survival pathway [18]. Different cells isolated 
from RasGAPD455A/D455A showed an increase sensibility to stress-induced apoptosis. 
Remarkably, macrophages showed no significative difference when treated with increasing 
doses of UV light or cisplatin. This may be explained by the macrophages physiology. The 
assessment of increased sensibility to stress-induced apoptosis should be performed in a 
greater number of primary cell lines. 
Preliminary experiments using γ irradiation and intraperitoneal injection of sublethal doses 
of cisplatin did not show any significative difference. These results indicate that RasGAP is 
not necessary for organism to survive after a sublethal stress. This is probably due to the 
presence of redundant survival mechanisms. 
Caspases are involved in the development and maintenance of the immune system [21, 22] 
RasGAP cleavage does not appear to play a role in the development of the different 
haematopoietic cell lines (Figure 2A), since no significative difference was observed 
between RasGAPD455A/D455A and RasGAPwt/wt mice, and the variations could be attributed to 
inter-individual differences.  
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However, RasGAPD455A/D455A derived splenocytes showed an increased proliferative rate 
(measured by MTT assay) when stimulated with and anti-CD3 antibody. Nevertheless, these 
results should be confirmed. Further experiments, should aim at identify the nature of the 
proliferating population (since splenocytes are a mixed cell population) and clarify whether 
the increased proliferative rate is due to increased proliferation of increased apoptosis in the 
less proliferating cells. 
Transaortic constriction (TAC) leads to hemodynamic overloading that in turn induces 
cardiac hypertrophy. Preliminary experiments in which TAC was performed in 
RasGAPD455A/D455A and RasGAPwt/wt mice showed that an increased hypertrophy in the 
RasGAPD455A/D455A mice that was confirmed by an increased Heart Weight (mg)/Body Weight 
(gr) ratio. Even though biochemical and histological characterizations remain to be done, we 
can hypothesize that increased apoptosis in KI hearts would induce proliferation as a 
compensatory mechanism, leading to an increased hypertrophy. 
Even if a part of the results is still preliminary we can conclude that RasGAP cleavage it is 
not involved in the develoment and homestoasis of unchallenged mice. When mice were 
challenged the responses varied with the different stimuli, suggesting the existence of 
redundant protective mechanism. These result also imply that RasGAP cleavage might be an 
important survival factor in response to specific stress-inducers. 
3.4 Materials and Methods 
3.4.1 Generation of the RasGAP D455A knock-in mice. 
The strategy used to create the targeting vector is presented in the supplementary Figure 1. 
The genomic clones containing the sequences required to construct the D455A targeting 
vector were obtained by screening the RPCI - 22 (129S6/SvEvTac) Mouse BAC Library 
(Bacpac Resources Children's Hospital Oakland) [23] with a probe corresponding to 
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nucleotides 7137306-7136366 of the Mus musculus chromosome 13, strain C57BL/6J 
(accession n° NT_039589.2). Three clones were identified as carrying the required sequence 
(RP22 - 250D10, RP22 - 268I2 and RP22 - 257P13). 
Each clone was digested with SwaI in order to release a ~10 kb fragment containing parts of 
the genomic sequence (RasGAP exons 9-10-11) necessary to construct the targeting vector. 
The 10 kb bands were subcloned in the EcoRV restriction site of pBluescript II SK + 
(Stratagene). A plasmid containing RasGAP exons 9-10-11 was identified by PCR and 
called RasGAP exons 9-10-11.blu. From this plasmid, a blunt-ended 6.5 kb BstXI fragment 
[nucleotides 7139579-7145879 from the Mus musculus chromosome 13 genomic contig 
(accession n° NT_039589.2)] was subcloned in the EcoRV restriction site of pBluescript II 
SK + to generate the 5’ homology arm composed of parts of introns 8 and 9 and exon 9 (the 
resulting plasmid was called RasGAP exon 9.blu). A 2.6 kb HindIII fragment from RasGAP 
exons 9-10-11.blu (nucleotides 7138985-7136418 from the chromosome 13 genomic contig) 
was subcloned in the HindIII restriction site of pcDNA3 to generate the 3’ homology arm 
composed of parts of introns 10 and 11 and exon 11 (the resulting plasmid was called 
RasGAP exon 11.dn3). 
A 590 pb fragment (called the Vital Region [VR] as it encodes amino acid 455 of RasGAP) 
containing exon 10 and connecting the 5’ and 3’ homology arms was PCR amplified from 
the BAC clones described above using the Pwo polymerase (Roche Applied Science, 
catalogue number 04 340 868 001), sub-cloned into the SmaI and NotI sites pBluescript II 
SK+, and sequenced twice to confirm that no PCR-generated errors occurred (the resulting 
plasmid was called Lox 66 - RasGAP Exon 10.blu). 
The mutation of the caspase cleavage site in exon 10 was done using the megaprimer PCR 
mutagenesis method  [24] using the following primers: 
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1) sense primer for the first PCR: AA GTA CTG AAC GAC ACT GTG GCC GGC AAG 
GAG ATC TAT AAC ACA AT (sequence 641-685 from the Mus musculus RasGAP mRNA 
[gi 21703899] carrying an A to C mutation (underlined) that destroys the first RasGAP 
caspase cleavage site by substituting an aspartate (D) residue for an alanine (A) [16] and two 
additional silent mutations (bold) that, together with the D to A mutation, create a new 
restriction site recognized by the NaeI and NgoMIV endonucleases. 
2) anti-sense primer for the first PCR: TACCTAGCATGAACAGATTG (a random 
sequence not found in the plasmid) GCGGCCGC (NotI) GTTCTAAAACCCTGGTTATA 
(3' terminal sequence of the Vital Region; sequence 42026-42007 of Mus musculus BAC 
clone RP23-222G16 [gi 29367036]). 
3) sense primer for the second PCR: CGTA CCCGGG (SmaI) 
AGTAGGTGGGTTCAGGAGCAG (sequence 42007-42026 of Mus musculus BAC clone 
RP23-222G16 [gi 29367036]). 
4) anti-sense primer for the second PCR: TACCTAGCATGAACAGATTG (the same 
random sequence found in primer 2). 
The mutated PCR product was digested with SmaI and NotI and subcloned into the 
SmaI/NotI sites of pBluescript II SK + [generating plasmid RasGAP exon 10 (D455A).blu]. 
The LoxP Targeting Vector (LTV) [kindly provided by Dr. Olivier Staub] was used as a 
backbone to construct the targeting vector. The LTV vector consists of a Neo cassette (PGK-
Neo) flanked with two LoxP sites and a Herpes Simplex Virus - Timidine Kinase gene 
(HSV-TK). 
RasGAP Exon 11.dn3 was digested with HindIII and the resulting 2.6 kb fragment was 
ligated into the HindIII site of LTV (generating plasmid LTV - Lox-Neo-Lox - RasGAP 
Exon 11). The 0.6 kb SmaI/NotI fragment of RasGAP Exon 10 (D455A).blu was ligated into 
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the SmaI/NotI sites of RasGAP Exon 9.blu, creating plasmid RasGAP Exons 9-10 
(D455A).blu.  
Finally, the SalI/NotI 7 kb fragment of RasGAP Exons 9-10 (D455A).blu was inserted into 
the SalI/NotI sites of LTV - Lox-Neo-Lox - RasGAP Exon 11 plasmid to obtain the final 
D455A Targeting Vector [plasmid RasGAP Exons 9-10 (D455A)-Lox-Neo-Lox-RasGAP 
Exon 11]. 
The targeting vector electroporation, clone selection and injection into D57/BL6 blastocystes 
was performed at the Transgenic Animal Facility of the Lausanne University. 
3.4.2 Chemicals and antibodies 
The anti-phospho-(serine 473)-Akt rabbit polyclonal IgG antibody was from Cell Signaling 
Technology (catalogue number 9271). The anti-RasGAP antibody directed at the Src 
homology domains of RasGAP was from Alexis (catalogue number ALX-210-860). Glucose 
was from Merck (catalogue number 1.08342). Cisplatin, staurosporine, 5(6)-
carboxyfluorescein diacetate N-succinimidyl ester (CFSE), propidium iodide and 
Concanavalin A from C. ensiformis were from Sigma (catalogue number, P4394, S4400, 
21888, P4170 and C0412, respectively). Annexin V-FITC and the 70 µm nylon mesh Cell 
strainer were from BD Biosciences (catalogue number 556419 and 352350, respectively). 
3.4.3 Bone marrow-derived macrophages. 
Mice were killed by cervical dislocation and soaked with 70% ethanol. A mid-back incision 
was performed to remove the skin from the lower part of the body. Feet were cut and hind 
legs were removed and placed in a Petri dish containing sterile medium. Excess muscle was 
removed for the legs, the knee joint was dislocated and the bone tips cut off. Total bone 
marrow cells were obtained by flushing the femur and tibia with 4 ml of RPMI-1640, 10% 
heat-inactivated fetal calf serum (FCS) and penicillin (100 units/ml) / streptomycin (100 
µg/ml) (Invitrogen, catalogue number 61870, 10270 and 15140, respectively) using a 27-
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gauge needle. Cell suspensions were passed up and down six times through an 18-gauge 
needle in the same medium to disperse cell clumps. Finally, the cells were centrifuged 3 
minutes at 190 x g and residual erythrocytes were eliminated by hypotonic lysis following 
resuspension of the cell pellet in 1 ml of ACK-lysing reagent (0.15 M NH4Cl, 1.0 mM 
KHCO3, 0.1 mM EDTA) for 5 minutes. The reaction was stopped by the addition of 10 ml 
fresh medium and the cells were counted using Trypan blue. 
To induce differentiation approximately 107 bone marrow cells were seeded in 15 cm 
bacteriological plates in Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen, 
catalogue number 31980), 10 % FCS, 50 µM β-mercaptoethanol supplemented with 30 % 
(v/v) of L929 cell conditioned medium (containing M-CSF) [25] (see below) and kept in 
culture for 1 week. When differentiated, the cells were washed with PBS and harvested by 
adding 10 ml of Versene  (0.2 g/L EDTA•4 Na+ in phosphate-buffered saline) (Invitrogen 
catalogue number 15040) and incubation at 4°C for 30 min. 
3.4.4 L929 conditioned medium 
L929 conditioned medium was obtained by plating L929 cells in 150-cm2 tissue culture 
flasks (BDbiosciences, catalogue number 355000) at an initial density of 3 × 104 cells per ml 
in 100 ml of RPMI-1640, 10% heat-inactivated fetal calf serum and penicillin/streptomycin. 
After 7 days in culture, the culture supernatant was filtered, aliquoted in 50-ml tubes, and 
stored at -20°C. 
3.4.5 Mouse splenocytes. 
Mice were killed by cervical dislocation and soaked with 70% ethanol. The peritoneal cavity 
was opened, the spleen isolated and placed in a 15 ml falcon tube, filled with RPMI 1640, 
10% FCS and penicillin/streptomycin. In a sterile tissue culture hood, the spleen was placed 
into the cell strainer and, using the plunger end of a syringe, mashed through the cell strainer 
into a Petri dish. Finally, the cells were centrifuged 3 minutes at 190 x g and residual 
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erythrocytes were eliminated by hypotonic lysis (see above). 
3.4.6 Western Blot Analysis. 
Cells were lysed in monoQ-c buffer [16]. The primary antibodies were revealed with a 
1/5000 dilution of an Alexa Fluor 680-conjugated anti-rabbit antibody (Molecular Probes, 
Eugene, OR; cat. no. A21109) or an IRDye 800-conjugated anti-mouse antibody (Rockland, 
Gilbertsville, PA; cat. no. 610-132-121) and subsequently visualized with the Odyssey 
infrared imaging system (LICOR Biosciences, Bad Homburg, Germany).  
3.4.7 Southern Blot. 
DNA was purified from 2 to 5 mm mice tail biopsies. Briefly, tails were digested overnight 
at 56° C in 750 µl digestion buffer (100 mM NaCl; 10 mM Tris-HCl pH 8; 25 mM EDTA 
pH 8; 0.5 % SDS; 0.1 mg/ml proteinase K). The following day, samples were mixed 5 
minutes at maximum speed in an Eppendorf Thermomixer Comfort mixer. Two hundred µl 
of a saturated solution of NaCl was added, the samples were mixed for 5 minutes at 
maximum speed in an Eppendorf Thermomixer Comfort mixer and centrifuged at maximum 
speed for 5 minutes in a benchtop Eppendorf centrifuge. The intermediate phase (~750 ml) 
was recovered and 500 µl of isopropanol was added. Samples were mixed and centrifuged as 
mentioned above. Finally the DNA pellet was washed with cold 70% ethanol and 
resuspended in 90 µl of Tris-EDTA buffer (10 mM Tris; 1 mM EDTA; pH 8.0). 
DNA (30 µl) was digested with XhoI and BamHI overnight and separated on a 0.8 % 
agarose gel. The gel was then washed sequentially in 0.25 M HCl, for 10 minutes, 0.4 M 
NaOH for 30 minutes, in neutralizing solution (1.5 M NaCl; 0.5 M Tris-HCl pH 7.2; 1 mM 
EDTA pH 8) for 20 minutes and 5 minutes in 20x SSC (3 M Sodium Chloride; 0.3 M 
Sodium Citrate, pH 7.0). 
The gel was transferred by capillarity overnight in 20x SSC to an Amersham Hybond™-N+ 
membrane (GE Healthcare; catalogue number RPN303B). The following day, the membrane 
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was briefly washed in 2x SSC, air-dried and UV-fixed with 120 mJ (UV Stratalinker 2400; 
Stratagene). The membrane was then probed overnight in hybridization solution (0.5 M 
Sodium Phosphate pH 7.2; 7% SDS, 1mM EDTA and 1% BSA) with a probe corresponding 
to nucleotides 7134443-7133563 of the Mus musculus chromosome 13 genomic contig, 
strain C57BL/6J (accession n° NT_039589.2). The probe was labelled by random priming 
(Random Primed DNA Labelling Kit, catalogue number 1 004 760; Roche Applied Science). 
The probe recognizes a 9.3 band corresponding to the wild-type allele and a 6 kb band 
corresponding to the targeted allele. Finally, the membrane was washed twice in washing 
solution (40 mM Sodium Phosphate pH 7.2; 1% SDS; 5 mM EDTA and 0.5 % BSA) and 
visualized using a BioRad® Personal Molecular Imager FX™ System. 
3.4.8 Apoptosis Measurements 
Apoptosis was determined by scoring the number of cells displaying pyknotic nuclei (a 
pyknotic nucleus is condensed and reduced in size and usually displays increased staining 
capacity). Nuclei of live cells were labelled with Hoechst 33342 (10 µg/ml final 
concentration) for 5 min, and the cells (at least 400 per condition) were then analyzed using 
an inverted Zeiss Axiovert 25 microscope equipped with fluorescence (HBO/AC) and 
transmitted light optics and a 40x objective (Zeiss 440865; LD Achroplan 40x/0.60 Korr 
Ph2; /0-2). 
3.4.9 PCR. 
The presence of the D455A mutation was detected by PCR of genomic DNA isolated from 
tail biopsies (see Southern Blot for details) followed by an NgoMIV restriction digestion of 
the PCR product. Briefly, sense AGTAGGTGGGTTCAGGAGCAG and antisense 
GTTCTAAAACCCTGGTTATA primers were used to amplify a band of 0.6 kb. 
Touchdown PCR was performed as follows: one 5 minute-incubation at 94° C; 10 cycles 
using the following conditions: 30 seconds at 94° C, 30 seconds at 65° C for the first cycle 
Chapter 3 
73 
or at a temperature decremented by 1°C in each subsequent cycle, and 45 seconds at 72° C; 
25 cycles using the following conditions: 30 seconds at 94° C, 30 seconds at 55° C; 45 
seconds at 72° C; a final elongation of 7 minutes at 72° C. The reactions were performed 
using Taq DNA Polymerase (Roche Applied Science, catalogue number 11647679001). At 
the end of the reaction, 20 µl of a mix containing NgoMIV (Promega, catalogue number 
R7171) were added and samples digested overnight at 37° C. The PCR products were 
analyzed on 1.5 % agarose gel containing ethidium bromide. The presence of the mutation 
was assessed by the appearance of a 0.3 kb band corresponding to digestion of the mutated 
PCR product by NgoMIV. 
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4 EXPRESSION OF THE N-TERMINAL FRAGMENT OF RASGAP IN 
PANCREATIC BETA CELLS INCREASES THEIR RESISTANCE TO 
STRESSES AND PROTECTS MICE FROM DIABETES 
4.1 Introduction 
Elimination of pancreatic β cells by apoptosis is a culminating event leading to type 1 [1] 
and possibly type 2 diabetes [2, 3]. The development of tools favoring β cell survival in 
patients is therefore of critical importance to delay or prevent the development of the 
disease. Moreover, compounds that increase β cell survival would be extremely useful in 
islet transplantation procedures, such as the Edmonton Protocol, to increase the yield of islet 
cells production from diseased donors and to ameliorate the rate of successful engraftment of 
the pancreatic islets in the host. 
Apoptosis is induced when a family of proteases called the caspases is activated [4, 5]. These 
enzymes cleave a subset of cellular proteins, inducing the characteristic biochemical and 
morphological features of apoptosis. Pancreatic islet cells undergo apoptosis in response to 
many stimuli [6], including anoxia [7], nutrient deprivation [8], hyperglycemia [9] and 
inflammatory cytokines [10]. Counteracting the pro-apoptotic effects of caspases would 
therefore be advantageous to render islet cells more resistant to a series of noxious stimuli.  
A very potent anti-apoptotic mediator is the Akt kinase [11]. Akt is able to stimulate the 
NFκB pathway [12-14] and in some cells types, Akt-induced NFκB activation is required for 
cell survival [13]. In β cells though, NFκB, depending on how it is activated, can be 
detrimental [15-19]. Therefore in contrast to many cell types, expression of active Akt in β 
cells can lead to apoptosis. This has indeed been confirmed in vivo in mice expressing an 
Akt1 transgene under the control of the insulin promoter [20]. In this model, the presence of 
Akt1 in β cells increased the apoptotic rate by at least 10 times compared to control β cells. 
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Despite inducing an increase in the basal apoptotic rate, Akt1 inhibited streptozotocin-
induced β cell apoptosis. Why Akt1 can either favour (e.g. in basal conditions) or inhibit β 
cell death (upon streptozotocin injection) is unclear. But, as Akt1 expression in β cells 
induces a two- to three-fold increase in insulin blood levels [20] and since insulin protects β 
cell against cell death [21, 22], the resistance of β cells towards streptozotocin in Akt1 
transgenic mice could be an indirect consequence of augmented insulin blood 
concentrations. 
Akt, besides its ability to regulate cell death, also has the potential to modulate cell 
proliferation and cell growth [11]. For example, the specific expression of Akt1 in β cells in 
mice increased the number of islets in the pancreas and the size of the β cells, leading to 
increased β cell mass [20]. However, the number of β cells per islet was diminished [20]. 
Expression of an active form of Akt1 in β cells therefore generates two opposing forces: an 
increase in basal apoptosis and a stimulation of proliferation/growth. The potential beneficial 
effects of Akt1 activity in β cells are therefore mitigated by the increased susceptibility to 
cell death that is most likely mediated by the concomitant activation of NFκB. Thus, unless 
Akt is prevented from stimulating NFκB, it remains unclear whether expression of an active 
form of Akt1 is advantageous for the long-term survival and functionality of β cells.  
RasGAP, a regulator of Ras and Rho, is a caspase-3 substrate bearing two cleavage sites. 
RasGAP is cleaved in a stepwise manner as caspase activity increases in cells. At low 
caspase-3 activity, RasGAP is cleaved only once, generating an N-terminal fragment, called 
fragment N, that induces a potent anti-apoptotic response [14, 23]. At higher caspase 
activity, fragment N is further processed into two additional fragments, called fragments N1 
and N2, that no longer protect cells but rather promote apoptosis [23, 24]. Fragment N 
induces cell survival by activating the Ras-PI3K-Akt pathway [14]. Importantly, not only 
does fragment N not require NFκB activity for its anti-apoptotic properties, it inhibits the 
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ability of Akt to activate NFκB [14]. This indicates that different ways of activating Akt (i.e. 
via expression of an active mutant of Akt or via expression of fragment N) does not lead to 
the same cellular responses. We have recently demonstrated that expression of fragment N in 
β cells in vitro leads to the stimulation of Akt-dependent protective signals while blocking 
the ability of Akt to activate the pro-apoptotic NFκB pathway [25]. To determine whether 
fragment N would display its protective functions in an in vivo setting, a transgenic mouse 
was generated that expresses fragment N under the control of the rat insulin promoter to 
restrict its expression in pancreatic β cells. This mouse model displayed an increased 
resistance to experimentally induced diabetes and its β cells were less susceptible to 
apoptosis induced by a variety of death stimuli. Fragment N and the pathway it regulates 
represent therefore a potential target for the development of anti-diabetic tools. 
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4.2 Results 
4.2.1 Generation of a transgenic mouse, expressing fragment N in pancreatic β cells. 
A transgenic vector was constructed (see Materials and Methods) to encode an HA-tagged 
form of fragment N bearing the D455A mutation (preventing it from being cleaved by 
caspases) under the control of the rat insulin promoter (RIP) and regulatory sequences of the 
simian virus 40 (SV40) gene (Figure 1A). The construct was injected into FVB/N oocytes 
and transgene-positive mice where identified by Southern blotting (Figure 1B). In total 4 
founder mice were obtained. The data presented here were all generated from founder #1 
(labelled mouse 5 in Figure 1B). By comparison with the endogenous insulin promoters, it 
was estimated that founder #1 bore 12-15 copies of the transgene in its genome (Figure 1B). 
To determine the expression pattern of fragment N in the transgenic line, lysates from 
pancreatic islets, liver, brain, and spleen were analyzed by Western blotting using antibodies 
specific for the HA tag or for the N-terminal part of RasGAP. Figure 1C, shows that 
fragment N was, as expected, only expressed in islet cells. Immuno-fluorescence analysis 
revealed that fragment N was restricted to the endocrine part of the pancreas (Figure 1D) and 
that the vast majority of fragment N-expressing cells corresponded to β cells (i.e. insulin-
containing cells) (Figure 1E). As expected, the presence of fragment N in islet cells led to a 
strong Akt activation (Figure 1F). 
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4.2.2 Fragment N expression does not affect islet morphology and cellularity. 
Expression of fragment N in insulinomas and islet cells leads to Akt activation (Figure 1F 
and [25]). Since Akt signalling has the potential to stimulate cell survival and proliferation 
[28] and since transgenic mice expressing a constitutively active form of Akt (myr-Akt) 
show an increase in both β-cell size and total islet mass [20], the presence of fragment in 
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islets might affect the morphology and cellularity of the endocrine pancreas. However, 
neither the proportion of α and β cells (Figure 2A), nor the insulin content of the pancreas 
(Figure 2B) were affected by the presence of fragment N. Moreover, the size of the islets did 
not appear to be different in RIP-N transgenic mice compared to control mice (Figure 2C). 
Finally, the percentage of cells positive for the nuclear protein Ki67 that is preferentially 
expressed in dividing cells was similar in both types of mice (Figure 2D). These results 
indicate that fragment N does not favour β cell proliferation in an in vivo setting and that it 
does not affect the normal development of the endocrine pancreas. 
4.2.3 Islets from RIP-N transgenic mice display increased resistant to stress-induced 
apoptosis. 
In wild-type mice, the basal apoptotic rate in islets is undetectable [20] to extremely low 
(0.06%). In contrast, islets from transgenic mice expressing a constitutively active form of 
Akt show a marked increase in β cell apoptosis. Islets isolated from RIP-N mice were more 
resistant than those isolated from control mice when subjected to a variety of stress stimuli, 
including inflammatory cytokines, hypoxia, the free fatty acid palmitate, and high glucose 
concentrations (Figure 3A-C). These results demonstrate that fragment N efficiently protects 
pancreatic β cells against various conditions and stimuli, including some that are associated 
with the development of type 1 and type 2 diabetes (e.g. inflammatory cytokines and free 
fatty acids). 
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4.2.4 Fragment N does not adversely affect β cell functions in vivo. 
Transgenic mice expressing a non-degradable form of IκBα under the control of Pdx1 
promoter, which drives its expression in the β cells of the pancreas, display impaired 
glucose-induced insulin secretion [29]. Fragment-N by blocking NFκB activity [14, 24] 
could potentially similarly affect insulin secretion. However, fragment N expression in β 
cells did not modify glycaemia under non-fasted (Figure 4A) or fasted (Figure 4B, first 
points in the graphs) conditions. Moreover, the ability of the transgenic mice to metabolize 
glucose, assessed by intraperitoneal glucose tolerance tests, was not negatively affected by 
the presence of the transgene in β cells (Figure 4B). There was even a tendency in RIP-N 
females to respond better to hyperglycaemia (Figure 4B, left panel). These results indicate 
that fragment N does not compromise the ability of β cells to secrete insulin in response to 
augmented glucose blood levels. 
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4.2.5 RIP-N transgenic mice are protected against streptozotocin-induced diabetes. 
Multiple low dose-streptozotocin injections in mice induce islet inflammation, ultimately 
leading to β cell loss and diabetes [30]. This model is thought to mimic the development of 
type 1 diabetes in humans [31]. Using this protocol, it was found that RIP-N mice only 
developed moderate diabetes compared to control mice (Figure 5). This indicates that the 
presence of fragment N in β cells increase their resistance in vivo to diabetes-inducing 
conditions.  
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4.3 Discussion 
Apoptosis, which is the cause of β cells death in patients with type 1 diabetes [32], might 
also participate in the loss of β cell mass observed in type 2 diabetes [33-36]. The notion, 
however, that there is a decrease in β cell mass in type 2 diabetes has been controversial for 
a number of years. Nevertheless, if one considers those studies using well-preserved 
pancreases obtained from autopsies, it appears that there is a 3-10 fold increase in the rate of 
β cell apoptosis in type 2 patients compared to control subjects [37]. These results indicate 
that failure to compensate for insulin resistance could result from decreased β cell mass 
mediated by apoptosis. 
Understanding the pathways leading to β cell death and β cell protection might therefore be 
of crucial importance to find new approaches to treat diabetic patients. Procedures to block β 
cell death could not only potentially inhibit the development of diabetes but might also be 
useful in the context of islet transplantation where apoptosis has been shown to adversely 
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affect the number of islets that can be implanted in patients. Here we present an in vivo 
model - the RIP-N transgenic mice - where the N-terminal fragment of RasGAP (called 
fragment N) effectively protects pancreatic β cell against apoptosis without affecting their 
ability to appropriately secrete insulin in physiological conditions. 
Hyperlipidaemia, a risk factor for the development of diabetes [38], can cause β cell 
apoptosis [39, 40]. Islets isolated from RIP-N mice underwent less apoptosis in conditions 
mimicking hyperlipidemia (i.e. high concentrations of palmitate) compared to control islets. 
Hyperglicemia, which leads to β cells dysfunction and death [6], also induced less apoptosis 
in fragment N-expressing islets. Finally, RIP-N transgenic islets were more resistant to IL1β, 
TNFα, and IFNγ-induced death. Interestingly, these inflammatory cytokines, known to be 
involved in the development of type 1 diabetes, have also been shown to be produced at high 
concentrations in diabetic-prone obese patients [41, 42]. These observations suggest that the 
protective signals elicited by fragment N can counteract pro-diabetic conditions (e.g. 
hyperglycemia, hyperlipidemia, presence of inflammatory cytokines) that are deleterious for 
β cells. 
Islet transplantation can restore insulin independence in patients with unstable forms of type 
1 diabetes [21, 22]. This promising therapeutical approach suffers however from a shortage 
of donor pancreatas. The situation is worsened by the fact that there is up to 70% of the 
transplanted islet mass that fails to engraft in the host as a result of apoptosis [43]. It is in 
fact estimated that, unless this loss through apoptosis is severely reduced, islet 
transplantation might not become a widely accepted treatment modality [44]. A critical 
parameter that negatively influences β cell survival in the islet transplantation procedure is 
the prolonged hypoxia experienced by the islets during their revascularization in the liver of 
the host [45, 46]. When exposed to hypoxia, islets isolated from RIP-N mice showed a 
marked reduction in apoptosis compared to control islets. This indicates that expression of 
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fragment N in islet cells can potentially increase the efficacy of islet transplantation by 
reducing hypoxia-induced cell death. 
Much work on the cellular mechanisms controlling cell death and survival has been 
performed within the last few years. This knowledge has been used to manipulate β cells in 
order to increase their survival capacities. One strategy was based on Akt because it is a 
potent anti-apoptotic kinase in many cell types [47]. Transgenic mice expressing an active 
form of Akt (myr-Akt) in β cells in mice have larger β cell and bigger islets [20]. These 
transgenic mice are resistant to experimentally induced diabetes but, paradoxically, their β 
cells have a much increased basal apoptotic rate [20]. Conceivably, this higher apoptotic rate 
is compensated by increased β cell renewal to maintain an adequate β cell mass. As NFκB 
activation can induce β cell death [6] and because Akt stimulates NFκB [12], the increased 
apoptosis response observed in myr-Akt-expressing β cells likely results from the 
stimulation of the NFκB pathway. Indeed, prevention of NFκB activation using a dominant-
negative IκB mutant allows mice to resist streptozotocin-induced diabetes [48] [19]. NFκB 
inhibition might however not always be protective against diabetes as indicated by the 
increased susceptibility of NOD mice to develop diabetes when their β cells express the 
dominant-negative IκB mutant [19]. Additionally, it has been shown that expression of a 
dominant-negative IκB mutant in β cells in mice can inhibit glucose-stimulated insulin 
secretion [29]. 
The RIP-N mice appear to lack some of the defects associated with the models described 
above. The activation of Akt by fragment N in the β cells of RIP-N mice is not accompanied 
by an increased basal apoptotic rate, most likely because fragment blocks Akt from 
stimulating NFkB. Moreover, in contrast to mice expressing an active form of Akt in β cells, 
RIP-N mice do not display islet and β cell hyperplasia. Finally, RIP-N mice have no defect 
in glucose-induced insulin-secretion. Transgenic mice over-expressing proteins of the IAP 
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(inhibitor of apoptosis) family specifically in the β cells have been generated. Similarly to 
RIP-N mice, their β cells are less susceptible to apoptosis and this is not accompanied by 
alterations in islet morphology and function [49]. It will therefore be important to define if 
there is a link between fragment N and IAPs that could explain the protective function of 
fragment N in β cells. A detailed characterization at the molecular level of the pathways 
regulated by fragment N might ultimately lead to the identification of new strategies to 
preserve β cell mass. 
4.4 Materials and Methods 
4.4.1 Cell Culture. 
Isolated islets were maintained in RPMI 1640 medium (catalog number 61870; Invitrogen) 
containing 10% decomplemented fetal calf serum (catalogue number 10270; Invitrogen), 10 
mM HEPES (catalog number H-3537; Sigma), 2 mML-glutamine (catalog number G-7513; 
Sigma), 1 mM sodium pyruvate (catalog number S-8636; Sigma) and penicillin (100 
units/ml)/streptomycin (100 µg/ml) (catalogue number and 15140; Invitrogen) at 37 °C and 
5% CO2. 
4.4.2 Chemicals and Antibodies 
The anti-phospho-(serine 473)-Akt rabbit polyclonal IgG antibody was from Cell Signaling 
Technology (catalogue number 9271). The monoclonal antibody specific for the 
hemagglutinin (HA) tag was purchased as ascites from BabCo (Richmond, CA; catalogue 
number MMS-101R). This antibody was adsorbed on HeLa cell lysates to decrease 
nonspecific binding [23]. The anti-RasGAP antibody directed at the Src homology domains 
of RasGAP was from Alexis (catalogue number ALX-210-860). The anti-insulin guinea pig 
polyclonal IgG antibody (catalogue number 4010-01) and the anti-glucagon rabbit 
polyclonal IgG antibody (catalogue number 4030-01F) were from Linco Research Inc. The 
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anti mouse Ki67 rat monoclonal IgG antibody, the EnVision+ system horse radish 
peroxidase (HRP)-labelled polymer anti-rabbit or anti-mouse antibodies and the liquid 
DAB+ substrate chromogen system were from Dakocytomation Denmark A/S (catalogue 
number M7249, K4003, K4001 and K3468, respectively). The Anti-TdT rabbit polyclonal 
antibody was from AbD Serotec (catalogue number AHP597H). The FITC-conjugated goat 
anti-guinea pig IgG polyclonal antibody (catalogue number 106-095-003) and the Cy3 goat 
anti-mouse IgG polyclonal antibody (catalogue number 115-165-003) were from Jackson 
ImmunoResearch Europe. 
Glucose was from Merck (catalogue number 1.08342). Streptozocin, cisplatin, hydrogen 
peroxide and palmitate were from Sigma (catalogue number S0130, P4394, 349887 and 
P9767-5G, respectively). Cytokines (TNFα, interleukin-1β, and interferon-γ) were from 
Alexis (catalogue number ALX-520-002-C010, ALX-520-001-C010, and PBL-11500-2, 
respectively).  
4.4.3 Apoptosis Assay 
The extent of apoptosis was assessed by scoring the number of cells with pycnotic nuclei 
after Hoechst 33342 staining [25]. 
4.4.4 Hypoxia experiment 
The isolated islets were placed in the culture compartment (50 µl) of an airtight stainless 
steel chamber and maintained under strictly controlled metabolic conditions on a 
thermostabilized stage. The culture compartment was separated from the gas compartment 
by a thin (15 µm) transparent and gas-permeable silicone membrane (RTV 141, Rhône-
Poulenc, Lyon, France). 
After a period of stabilization of 90 min under normoxia (17% O2), islets were incubated in a 
hypoxic (0.7% O2) or normoxic atmosphere for 240 min. 
4.4.5 Mouse islet isolation 
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Islets were isolated after collagenase digestion as described [25]. 
4.4.6 PCR 
The presence of the transgene was detected by PCR amplification of genomic DNA isolated 
from tail biopsies (see “Southern Blot” section). Sense (ACTCCAAGTGGAGGCTGAGA) 
and anti-sense (TCCTTCCACAAACCCATAGC) primers were used to amplify a 
transgenic-specific band of 204 bps. As an endogenous control for the PCR reaction, the 
sense (AGGAACACACCATCATCCAGG) and anti-sense 
(GGGGAGAACTTGTCAATGAAACA) primers were used to amplify an 804 bp-band 
from the MHC class II I-Eα gene. Touchdown PCR was performed as follows: one 5 
minute-incubation at 94° C; 10 cycles using the following conditions: 30 seconds at 94° C, 
30 seconds at 65° C for the first cycle or at a temperature decremented by 1°C in each 
subsequent cycle, and 45 seconds at 72° C; 25 cycles using the following conditions: 30 
seconds at 94° C, 30 seconds at 55° C; 45 seconds at 72° C; a final elongation of 7 minutes 
at 72° C. The reactions were performed using Taq DNA Polymerase (Roche Applied 
Science, catalogue number 11647679001). The PCR products were analyzed on 1.5 % 
agarose gel containing ethidium bromide. 
4.4.7 Insulin quantitation 
The mice were euthanized by cervical dislocation and after a midline abdominal incision, 
pancreas was removed, placed in 2 ml of acid/ethanol (75% ethanol 1.5 % concentrated HCl) 
and homogenized using a Polytron PT 1200 homogenizer (Kinematica AG) until the 
pancreas was completely disaggregated. Once homogenized, 2 ml of acid/ethanol were 
further added to the samples and insulin was extracted by gentle rocking at 4° C overnight. 
Finally samples were centrifuged at 700 x g for 3 minutes and the supernatant was 
recovered. Insulin content, on the supernatant, was then quantified as previously described 
[25]. 
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4.4.8 Immuno-cytochemistry 
For immunofluorescence studies, 6-7 week old mice were anesthetized and heart-perfused 
for 5 minutes with PBS and with PBS/4% paraformaldehyde for 15 minutes. Pancreatas 
were extracted and post-fixed in PBS/4% paraformaldehyde for 2 more hours and incubated 
overnight in PBS/30% sucrose (sucrose used here as a cryoprotectant). The following day, 
pancreatas were frozen in liquid nitrogen and kept at -80° C until sectioned. Frozen 
pancreatas were fully embedded in Tissue-Tek® Optimal Cutting Temperature Compound 
(Sakura Finetek Europe B.V.; catalogue number #4583) and 20 µm sections were obtained 
with a Leica CM3050 S Cryostat and mounted on SuperFrost® Plus slides (Menzel GmbH 
& Co KG; catalogue number J1800AMNZ). Sections were washed three times 15 minutes 
with PBS and incubated one hour with the antibody diluent (AD) solution (10% goat 
serum/0.3% Triton X-100/2% BSA in PBS). Slides were incubated overnight with the 
appropriate dilution of the primary antibody. The following day, slides were washed three 
times with PBS for 15 minutes and incubated one hour with the proper dilution of the 
secondary antibody. The slides were further washed three times for 15 minutes in PBS, 
mounted and, 3 hours later, pictures were taken with a Zeiss AxioVis C1 microscope. 
4.4.9 Immuno-histochemistry 
Mice were euthanized by cervical dislocation. Pancreatas were removed, fixed in PBS/4% 
paraformaldehyde and paraffin embedded. Eight µm sections were de-paraffined in xylene 
and re-hydrated in graded alcohols and distilled water. During the re-hydration steps, 
endogenous peroxidase activity was blocked with methanol/hydrogen peroxide 1% for 15 
minutes. For TdT staining, antigen retrieval treatment was performed for 2 minutes at 121° 
C in 50 mM Tris-HCl, 1 mM EDTA (pH 9). Sections were blocked for 10 minutes with 10% 
goat serum in 50 mM Tris-HCl, 1 mM EDTA (pH 7.6) and rinsed in the same buffer. 
Primary antibodies were applied for 1 hour in 50 mM Tris-HCl, 1 mM EDTA, 0.5% BSA 
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(pH 7.6). The secondary HRP-coupled antibody (EnVision+ System, DakoCytomation) was 
applied for 30 minutes. A visualization reagent (3,3’-diaminobenzidine; DAB) was applied 
for 5 minutes and rinsed off in tap water. Sections were counterstained by Harris’s 
haematoxylin, re-hydrated and mounted. All the steps were performed at room temperature. 
Pictures were taken with a Zeiss AxioVis C1 microscope. 
4.4.10 Western Blot Analysis 
Cells were lysed in monoQ-c buffer [23]. The primary antibodies were revealed with a 
1/5’000 dilution of an Alexa Fluor 680–conjugated anti-rabbit antibody (Molecular Probes, 
Eugene, OR; catalogue number A21109) or an IRDye 800–conjugated anti-mouse antibody 
(Rockland, Gilbertsville, PA; catalogue number 610-132-121) and subsequently visualized 
with the Odyssey infrared imaging system (LICOR Biosciences, Bad Homburg, Germany). 
4.4.11 Southern Blot. 
DNA was purified from 2 to 5 mm mice tail biopsies. Briefly, tails were digested overnight 
at 56° C in 750 µl digestion buffer (100 mM NaCl; 10 mM Tris-HCl pH 8; 25 mM EDTA 
pH 8; 0.5 % SDS; 0.1 mg/ml proteinase K). The following day, samples were mixed 5 
minutes at maximum speed in an Eppendorf Thermomixer Comfort mixer. Two hundred µl 
of a saturated solution of NaCl was added, the samples were mixed for 5 minutes at 
maximum speed in an Eppendorf Thermomixer Comfort mixer and centrifuged at maximum 
speed for 5 minutes in a benchtop Eppendorf centrifuge. The intermediate phase (~750 µl) 
was recovered and 500 µl of isopropanol was added. Samples were mixed and centrifuged as 
mentioned above. Finally the DNA pellet was washed with cold 70% ethanol and 
resuspended in 90 µl of Tris-EDTA buffer (10 mM Tris; 1 mM EDTA; pH 8.0). 
DNA (30 µl) was digested with EcoRI overnight and separated on a 0.8 % agarose gel. The 
gel was later washed sequentially in 0.25 M HCl, for 10 minutes, 0.4 M NaOH for 30 
minutes, in neutralizing solution (1.5 M NaCl; 0.5 M Tris-HCl pH 7.2; 1 mM EDTA pH 8) 
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for 20 minutes and 5 minutes in 20x SSC (3 M Sodium Chloride; 0.3 M Sodium Citrate, pH 
7.0). 
The gel was transferred by capillarity overnight in 20x SSC to an Amersham Hybond™-N+ 
membrane (GE Healthcare; catalogue number RPN303B). The following day, the membrane 
was briefly washed in 2x SSC, air-dried and UV-fixed with 120 mJ (UV Stratalinker 2400; 
Stratagene). The membrane was then probed overnight in hybridization solution (0.5 M 
Sodium Phosphate pH 7.2; 7% SDS, 1mM EDTA and 1% BSA) with a probe corresponding 
to a 0.7 kb BamHI/EcoRI fragment from the RIP-vmos.xf3 plasmid that contains the RIP1 
promoter. The probe was labelled by random priming (Random Primed DNA Labelling Kit, 
catalogue number 1 004 760; Roche Applied Science). The probe recognizes a 2.8 kb 
transgene specific band and two 1.8 and 0.7 kb endogenous bands corresponding to the Ins1 
and Ins2 promoters. Finally, the membrane was washed twice in washing Solution (40 mM 
Sodium Phosphate pH 7.2; 1% SDS; 5 mM EDTA and 0.5 % BSA) and visualized using a 
BioRad® Personal Molecular Imager FX™ System. 
4.4.12 Transgenic lines. 
The transgenic construct (RIP-N.xf3) bears fragment N of RasGAP under the control of the 
rat insulin promoter (RIP). It was obtained by ligation of a blunt-ended BamHI/SalI 1.4 kb 
fragment from plasmid N-D157A.bs (obtained by ligation of a blunt-ended 1.4 kb 
BamHI/XhoI fragment from plasmid N-D157A.dn3 into the pBS II SK + plasmid 
[Stratagene] opened with EcoRV) with a blunt-ended XbaI/HindIII 4 kb fragment from RIP-
vMos.xf3 plasmid. The correctness and functionality of the plasmid were controlled by 
sequencing and transfection into insulinoma cell lines. Finally, a BamHI 2.8 kb fragment 
from RIP-N.xf3 was microinjected into FVB/N oocytes at the Transgenic Animal Facility of 
the Lausanne University. Four independent RIP-N expressing founders were obtained. Only 
the data pertaining to founder #1 are described here.  
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4.4.13 Blood glucose level measurements and intraperitoneal glucose tolerance test 
(IPGTT). 
Blood glucose content of mice under feeding or fasting (16 hours) conditions was 
determined with an Accu-Check Compact Plus glucometer (Roche Diagnostics). For the 
IPGTTs, fasted (16 hours) animals were injected intraperitoneally with 2 mg/kg glucose. 
Blood glucose levels were determined from a blood drop taken after a short incision of the 
tail tip at increasing time intervals (-30, 0, 15, 30, 60, 90, 120. 150 minutes) following 
glucose injection. 
4.4.14 Streptozotocin-induced diabetes. 
Type 1-like diabetes was induced by multiple low dose streptozotocin injections. Briefly, 4 
hour-fasted female RIP-N mice were injected intraperitoneally for 5 consecutive days with 
50 mg streptozotocin per kg of mice. Streptozotocin was prepared and diluted in citrate 
buffer pH 4.5 (sodium citrate 25 mM, citric acid 23 mM) just before injection. Blood 
glucose levels were assessed biweekly. 
4.4.15 Statistical Analysis. 
All the statistical analyses were done with Microsoft Office Excel 2003 SP1 using the two-
tailed unpaired Student’s t test. Significance is indicated by an asterisk when p < 0.05/n, two 
asterisk when p < 0.01/n and three asterisks with p < 0.001/n, where p is the probability 
derived from the t test analysis and n is the number of comparisons done (Bonferroni 
correction). 
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5 DISCUSSION AND PERSPECTIVES. 
5.1 General Discussion 
The work performed in our laboratory during the last years permitted us to describe the role 
played by RasGAP in the context of apoptosis. At caspase levels that do not induce 
apoptosis, RasGAP is first cleaved at position 455 and two fragments are generated 
(fragment N and fragment C) [1]. Surprisingly, cells unable to cleave RasGAP were 
rendered more sensitive to stress-induced apoptosis. Fragment N protects cells against 
apoptosis via the activation of the Ras/PI3K/Akt pathway. In addition, fragment-N is also 
able to inhibit NFκB activity. When caspase levels increase to a level that induces apoptosis, 
fragment N is further cleaved at position 157. This cleavage abrogates fragment N anti-
apoptotic properties and generates two smaller fragments, named N1 and N2. Interestingly, 
fragment N2 was found to sensitize cancer cells to genotoxin-induced apoptosis [1, 2]. 
In the present work we show that the activation of the Ras/PI3K/Akt pro-survival pathway 
mediated by fragment N relies on the presence of the uncleaved form of RasGAP. This fact 
shows, once more, that RasGAP can act as Ras effector. The role played by RasGAP in the 
activation of the fragment-N mediated survival pathway could be to act as a hypothetical 
scaffold protein that would bring Ras and its effectors in close proximity. RasGAP is found 
in high molecular weight complexes ([3] and unpublished data from our laboratory) and is 
cleaved at surprisingly low caspase activity levels. Considering these two facts together, we 
can think of a high molecular complex containing RasGAP and other proteins involved in 
the anti-apoptotic pathway. This complex could be located in close proximity to caspase 
activation sites, therefore forming a “caspase-activity sensing complex”. If this complex 
exists, it does not seem to be indispensable for mouse survival, since knock-in mice 
expressing a caspase-insensitive RasGAP mutant (RasGAPD455A/D455A) are viable and exhibit 
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normal development and homeostasis under normal conditions. RasGAPD455A/D455A mice were 
not differentially affected by sub-lethal doses of γ-radiation or chronical injections of sub-
lethal doses of cisplatin compared to wt mice. This might indicate that other safeguard 
mechanisms exist. However, some stress responses might rely on this pathway, since 
RasGAPD455A/D455A mice showed increased heart hypertrophy following transaortic 
constriction-mediated haemodynamic overloading. Nonetheless, fragment-N anti-apoptotic 
properties can be used for therapeutical purposes. As we showed in chapter 4, over-
expression of fragment-N in pancreatic ß-cells protected them against stress-induced 
apoptosis and protected the mice against experimentally induced diabetes.  
5.2 Perspectives. 
5.2.1 Fragment-N mediated Akt activation relies on full length RasGAP. 
The numerous questions raised by the implication of RasGAP in the anti-apoptotic response 
mediated by its cleavage fragments, require numerous answers. The presence of RasGAP in 
supra-molecular complexes, induced by low stress conditions, is currently being tested using 
gel filtration. This method has previously being notably used to identify and characterize the 
apoptosome [4] and inflammasome [5]. Using this method, the presence of RasGAP in high 
molecular fractions, induced by stress, is determined by western blot of fractions obtained 
after chromatographic separation of cell lysates. High molecular weight fractions containing 
RasGAP would be then subjected to immunoprecipitation with an anti-RasGAP antibody 
and the proteins associated with it identified by mass spectroscopy. 
Even though the structure of the C-terminal domain of RasGAP is currently known, nothing 
(except the SH3 domain structure [6]) is known about the structure of the N-terminal 
domain. The structures of both RasGAP and fragment-N are going to be determined by X-
ray crystallography to understand the role played by RasGAP N-terminal fragment in the 
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interaction with other proteins and the possible conformational changes mediated by caspase 
cleavage.  
5.2.2 RasGAP uncleavable knock-in. 
RasGAP cleavage does not seem to be involved in the regulation of caspase activity in 
haematopoietic cell development. However, RasGAPD455A/D455A derived splenocytes showed 
an increased proliferative rate (measured by MTT assay) when stimulated with an anti-CD3 
antibody. Nevertheless, these results should be confirmed. Further experiments, should aim 
at identifying the nature of the proliferating population (since splenocytes are a mixed cell 
population) and clarify whether the increased proliferative rate is due to increased 
proliferation or increased apoptosis in the less proliferating cells. 
Preliminary experiments in which transaortic constriction was performed in 
RasGAPD455A/D455A and RasGAPwt/wt mice, showed increased heart hypertrophy in the 
RasGAPD455A/D455A mice. These results should be further confirmed and the biochemical and 
histological characterizations performed. The results of the biochemical characterization 
would allow understanding the role played by RasGAP cleavage in this process. We can 
hypothesize that increased apoptosis in RasGAPD455A/D455A hearts would induce proliferation 
as a compensatory mechanism, leading to an increased hypertrophy.  
The capacity of fragment-N to modulate NFκB activity [2] will be tested in vivo. The role of 
NFκB during inflammation has been described as a positive feedback signal, inducing the 
expression of pro-inflammatory cytokines upon inflammatory signalling. The role of 
fragment-N NFκB inhibition will be studied in a model of heart inflammatory stress. If the 
role played by fragment-N NFκB inhibition is important, RasGAPD455A/D455A mice should 
have an exacerbated inflammatory response. Similar experiments can be performed by 
stressing the mice with lipopolysaccharide and following cytokine production, a direct 
indicator of NFκB activity. 
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5.2.3 Fragment-N protects against diabetes. 
The anti-apoptotic properties of fragment-N have proven to be a useful therapeutic tool in 
the context of diabetes. Fragment-N is able to efficiently protect islets against stress-induced 
apoptosis and mice against experimental diabetes. We have shown that fragment-N can be 
useful in the context of islet transplantation because it protects islet cells against hypoxia and 
cytokine-induced apoptosis, two important factors responsible for ß-cell demise prior 
transplantation. However, islet transplantation experiments should be performed to validate 
that fragment-N effectively enhances islet transplantation success rate and consequently 
diminishes the number of islets necessary for the procedure. 
Even if fragment-N protects islet, its practical use during transplantation procedure, would 
be very difficult to set up (mainly through viral infections). The understanding of the 
protective pathway induced by it is indispensable to be able to modulate these protective 
pathways. To dissect the survival pathways modulated by fragment N, microarray analysis 
should be performed. In addition this could lead the discovery of new downstream 
therapeutic targets.  
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Reagents 
 
1. HEPES buffer  (2X) pH 7.05 (23°C): 
 
1.1. Important note: always calibrate the pH meter before starting preparing the Hepes buffer. 
1.2. Composition. 
Chemicals Final concentration Source/Company Code/quantities 
    
NaCl 280 mM Fluka 71380 (1 kg) 
KCl 10 mM Fluka 60130 (1 kg) 
Na2HPO4 1.5 mM Merck 1.06586.0500 (500 g) 
D-glucose•H2O 12 mM Merck 1.08342.1000 (1 kg) 
HEPES 50 mM Fluka 54461 (250 g) 
    
 
1.3. Recipe. 
Chemicals For 500 ml 
  
NaCl 8 g 
KCl 0.38 g 
Na2HPO4 0.1 g 
D-glucose•H2O 1.1 g 
HEPES 5 g 
Adjust pH with NaOH (1 N, then 0.1 N) 
to 7.05 (23°C) 
See 1.4 
  
 
1.4. Add ddH2O to about 450 ml, then adjust to pH 6.8-6.9 with 1 N NaOH, and finally to pH 
7.05 with 0.1 N NaOH. Complete to 500 ml with ddH2O. Control that the pH is still at 7.05. 
1.5. Sterilize through a 0.22 µm 500 ml Stericups (Millipore #SCGPU05RE). Under a sterile 
hood, aliquot in 50 ml tubes (40 ml per tube). Write the lot number and the date on the tubes 
(the lot number should be indicated in your laboratory book). Store at –20°C.  
 
2. Others 
Chemicals Source/Compan
y 
Code/quantities Solvent [stock] Storage Sterile 
       
NaOH Fluka #71690 (500 g) ddH2O 10 N Room 
temp. 
no 
Chloroquine Sigma C6628 (25g) PBS 25 mM -20°C yes 
CaCl2•2H2O (MW 
147.02) 
Acros 207780010 (1 kg) ddH2O 2.5 M 4°C yes 
Gelatin Fluka 48722 (500 g) PBS 0.1% 4°C yes 
DMEM, glutamax 
I, 4.5 g/l glucose, 
sans sodium 
pyruvate 
Gibco 61965026 (500 
ml) 
    
Newborn calf 
serum (NBCS), 
heat inactivated 
Gibco 26010041 (500 
ml) 
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2.1. Preparation of NaOH solutions. 
NaOH can cause irreversible damage to the eyes. It is thus mandatory to wear glasses when 
preparing or using NaOH solutions. The preparation of 10 N NaOH involves a highly 
exothermic reaction, which can cause breakage of glass container. Prepare this solution with 
extreme care in plastic beakers. To 80 ml of H2O, slowly add 40 g of NaOH pellets, stirring 
continuously. As an added precaution, place the beaker on ice. When the pellets have 
dissolved completely, adjust the volume to 100 ml with H2O. Store the solution in a plastic 
container at room temperature (plastic containers are to be used because NaOH slowly 
dissolves glassware). Sterilization is not necessary. 
 
2.2. Preparation of a 25 mM chloroquine solution. 
In a 50 ml Falcon tube, add 0,645 gr of chloroquine and complete to 50 ml with ddH2O. 
Transfer to a 50 ml syringe and sterilize through a 0.22 µm filter (Millex – GV filters 
[Millipore #SLGV025LS]). Under a sterile hood, aliquote in 15 ml tubes (10 per tube). 
Write the lot number and the date on the tubes (the lot number should be indicated in 
your laboratory book). 
 
2.3. Preparation of a 2.5 M CaCl2 solution. 
In a 50 ml Falcon tube, add 18.4 g of CaCl2•2H2O and complete to 50 ml with ddH2O. 
Transfer to a 50 ml syringe and sterilize through a 0.22 µm filter (Millex – GV filters 
[Millipore #SLGV025LS]). Under a sterile hood, aliquote in 15 ml tubes (10 per tube). 
Write the lot number and the date on the tubes (the lot number should be indicated in 
your laboratory book). 
 
2.4. Preparation of a PBS/0.1% gelatin solution (500 ml). 
Add 0.5 g gelatin and 50 ml PBS 10X to 450 ml ddH2O in a glass bottle. Autoclave and 
store at 4°C. 
 
__________________________________________________________________________ 
Procedure 
 
Day 0. 
1. Plate cells in appropriate medium (use gelatinized dishes if required). 
Cells Number per 10 
cm dish 
Number per well 
(6 well-plates) 
medium Gelatinized 
dish 
     
HEK 293 and 
derived cell 
lines 
2.106 350’000 DMEM; 10% NBCS yes 
COS cells ?????  DMEM; 10% NBCS no 
     
 
1.1. Gelatinization of the dishes. 
Place the indicated volume of PBS/0.1% gelatin in the dish (tilt the plate to cover the entire 
surface with the solution). Wait at least 10 min. Just before adding the cells to the plates, 
aspirate the PBS/0.1% gelatin (do not allow the plates to dry). 
Dish size Volume of PBS/01% gelatin 
  
10 cm 2-5 ml 
6 well plates 0.5 ml 
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Day 1. 
2. Prewarm the HEPES 2X buffer in a 37°C water bath (at least 20 min). In case the buffer is 
thawed, mix very well before using. 
 
3. Add the DNA in the indicated volume of H2O. Add the corresponding volume of 2.5 M calcium 
solution. Mix 10 times by pipetting the solution up and down. Allow 20-30 min the solution to 
equilibrate. 
Cells Dish size Volume of 
medium in 
the dish 
DNA 
amount 
Volume of water in 
which the DNA is 
added 
Volume of 2.5 M 
calcium to be 
added 
      
HEK29
3 10 cm 10 ml 5-20 µg 450 µl 50 µl 
 6 well plate 2 ml 2 µg 90 µl 10 µl 
 12 well plate ? ? ? ? 
 24 well plate ? ? ? ? 
      
 
4. Add 25 µM chloroquine to the cell culture medium (not necessary to change the medium). 
Note: if the cells are grown in RPMI medium (e.g. HeLa cells), you have to replace it with 
DMEM because RPMI medium is not compatible with the present transfection technique. 
Dish size Volume of medium Volume of 
stock 
   
10 cm 10 ml 10 µl 
6 well plates 2 ml 2 µl 
 
5. Place the plates back in the incubator for at least 10 min. 
 
6. Add the indicated volume of prewarmed (37°C) 2X HEPES buffer to the DNA/calcium solution, 
mix 5 times by pipetting the solution up and down. Incubate for 1 minute exactly (starting from 
the moment the HEPES has been added to the DNA; not from the time when the mixing is 
finished). Put the DNA-HEPES mix in the culture medium (rock the plate left to right and up and 
down 2 times). 
 
Dish size Volume of HEPES 2X to be 
added 
  
10 cm 500 µl 
6 well plate 100 µl 
  
 
7. Incubate the cells at 37°C for 8-16 hours (always mention this time of incubation in your 
laboratory book). Replace the transfection medium with normal culture medium containing 
penicillin and streptomycin [use a 1:100 dilution of a Penicillin-Streptomycin Glutamine 100X 
solution (10’000 units/ml penicillin G; 10 mg/ml streptomycin sulfate; 29,2 mg/ml L-glutamine; 
10 mM sodium citrate; 0.14% NaCl {GibcoBRL #10378-016})] to avoid contamination (the 
DNA used for the transfection is generally not sterile!). 
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8. Expected transfection efficiencies (count at least 500 cells). 
Cells Transfection efficiency 
  
HEK293 30-80% 
COS 30-40% 
  
 
9. In your laboratory book, always mention how long after step 7 were the cells analyzed. 
 
References 
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Apparatus 
Transfer tank located in the drawers next to Christian’s office door. It is the transparent tank 
containing red-black electrode module inside. Gel cassetes and sponges are either in the drawer 
above the one containing the tanks or above the sink  in the middle of the lab.  
 
Materials and reagents 
3. Plastic sheets, commercial Enhanced chemiluminescence (ECL) solution and other reagents. 
3.1. Materials and reagents. 
Materials and reagents Source/Company Code/quantities 
   
Plastic sheets  
Kapak Tubular Roll Stock 
[9.5’’x250’ #5 Scotchpak 
(2 Mil)]. 
Kapak Parkdale Drivewe, 
Minneapolis, Minnesota 
55416 • 1681 
 
Tris Sigma T1503 5Kg 
Tween Acros p7949 100ml 
Milk   
ECL reagent 
Supersignal West Femto 
Substrate 
Pierce #34095 
Ponceau S Acros 161470250 (25 g) 
   
   
 
3.2. Ponceau S Staining Solution [0.1%(w/v) Ponceau S in 5% (v/v) acetic acid] 
• 1g Ponceau S  
• 50ml acetic acid  
• Make up to 1 liter with ddH2O  
Store at 4oC. Do not freeze. 
 
Alternative recipe:0.2% (w/v) Ponceau S in 3% (v/v) acetic acid. 
 
3.3. Tris-buffer saline (TBS; 18 mM HCl, 130 mM NaCl, 20 mM Tris pH 7.2) 
• 30ml HCl 
• 152g NaCl 
• 48g Tris base 
• Up to 1L dH2O 
 
3.4. TBS/tween 
• 19L dH2O 
• 1L 20X TBS 
• 0.1% Tween (final concentration) 
 
3.5. TBS/milk 
• 5% powdered milk (25g for 500ml of TBS/tween) 
• TBS/tween 
• Alternatively some primary antibodies work better if they are diluted in 5% BSA 
(5%BSA in TBS/tween) 
4. Home-made ECL solution. 
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4.1. Composition of the stocks. 
Chemicals Stock 
concentration 
Final 
concentration 
Source/Company Code/quantities 
     
Luminol (3-
aminophthalydrazi
de) 
250 mM (1 g in 
22.7 ml 
DMSO). Make 
1.5 ml 
aliquotes 
1.25 mM Sigma A-8511 (1 g) 
P-coumaric acid 90 mM (0.5 g 
in 33.3 ml 
DMSO). Make 
660 µl 
aliquotes. 
0.2 mM Acros 12109-0250 (25 g) 
Tris 1 M pH 8.5 100 mM Boehringer 
Mannheim 
708976 (1 kg); IBCM 
stock 
H2O2 30% 30% 0.01% Merck 1.07210.0250 (250 
ml) 
     
Solution 1: 2.5 mM luminol and 0.4 mM coumaric acid in 100 mM Tris pH 8.5. 
Solution 2: 0.02% H2O2 in 100 mM Tris pH 8.5. 
 
5. Home-made enhanced ECL solution Note: for the moment this is not working (use the above 
recipe instead). 
 
5.1. Composition of the stocks. 
Chemicals Stock 
concentration 
Final 
concentration 
Source/Company Code/quantities 
     
Luminol (3-
aminophthalydrazi
de) 
250 mM 1.25 mM Sigma A-8511 (1 g) 
p-iodophenol (in DMSO) 50 µM   
Tris 1 M pH 8.5 100 mM Boehringer 
Mannheim 
708976 (1 kg); IBCM 
stock 
H2O2 30% (8.82 
M) 
30% 2 mM Merck 1.07210.0250 (250 
ml) 
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Procedure 
 
1. General remarks. 
1.1. The conditions of incubation of the blots have to be adapted for each antigen and each 
antibody used. Therefore, the procedures presented in the following sections have to be 
considered as general guidelines and should not be assumed to work in all cases. Indications 
of possible improvements when the conditions are not found optimal will be mentioned. 
1.2. Always centrifuge the tubes containing the antibodies before usage. 
1.3. In principle, do not incubate two blots in the same bag. 
1.4. Never touch the blot with bare hands. Use gloves and move the blots with tweezers. 
1.5. The following procedure should be considered only for the small gels (see SOP12.1). 
 
2. Migration on gels. 
 
Percentage of acrylamide Separation 
  
8% 40-200 kDa 
10% 30-200 kDa 
12% 20-200 kDa 
4-20% 7-250 kDa 
8-16% 15-250 kDa 
  
 
3. Transfer to membranes. 
3.1. After migration, proteins are transferred to nitrocellulose filters (Schleicher and Schuell, 
BA83 0.2,µm, no. 401380) or PVDF membranes. Instruction on how to do this can be found 
in the same drawer as the material used for the transfer and for the SDS-PAGE (see SOP 
12.1). 
3.2. Transfer buffers. 
David has recently tested the two following buffers. According to him, transfer buffer II works 
better. 
 
Composition of transfer buffer I. 
Chemicals Stock solution Final 
concentration 
Source/Company Code/quantities 
     
CAPS 1M pH11 10 mM Acros 172621000 (100 g) 
Methanol  10% Fluka 65543 (5 l) 
     
CAPS 1M stock solution (500 ml): 110 g CAPS (MW 221.3) and 20 g NaOH in water. The pH 
should be 11. Store in the dark at 4°C. 
Prepare the transfer buffer (5 liters) directly in the transfer tank (50 ml CAPS 1M, 500 ml methanol, 
and water up to 5 liters).  
Methanol evaporation ensures that the buffer does not heat too much. Therefore the transfer buffers 
cannot be used too many times. Without methanol, the buffer would boil during the transfer! 
Transfer o/n at 600 mA. 
 
 
 
 
 
 
Composition of the transfer buffer II. 
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Chemicals 10X stock (1 
liter) 
Final 
concentration (1X 
transfer buffer) 
Source/Company Code [quantities] 
Tris 30.2 g 1 mM Biosolve ltd 20092388 [4 kg] 
Glycine 144 g 8 mM ACROS 120070050 [5 kg] 
SDS 10 ml of a 10% 
solution in water 
0.001% Biosolve ltd 19822359 [0.5 kg] 
Prepare the transfer buffer 1X (5 liters) directly in the transfer tank. 
Add 500 ml of the 10X buffer, 1 liter of methanol and water up to 5 liters. 
Transfer 5 hours at 660 mA. 
 
Currently the situation with the transfer buffers is like this: they are located above the sink were other 
materials for the transfer can also be found (sponges, etc.), There are several bottles of 10x transfer 
buffer. In order to make 1x transfer buffer, mix 100 ml of the 10X preparation with 700ml of water 
and 200ml of some alcohol (methanol or ethanol). 
 
 
3.3  After preparing the transfer tank, place the top on and plug it into a power supply machine 
(make sure that the plus and minus plugs are connected right: you do not want your 
proteins to be released on the wrong side directly into the transfer buffer). Transfer is 
usually preformed at 250 mA (constant amperage) for one hour or one hour and twenty 
minutes. 
3.4 Check if the protein markers have been transferred (one should see the markers on the 
membrane and not on the gel). 
 
4. This protocol should be used when there are no particular problems to get a strong signal 
 
4.1. Ponceau S Stain for Western blots. 
Background. This is a rapid and reversible staining method for locating protein bands on 
Western blots.  Sensitivity is somewhat less than Coomassie blue and produces reddish pink 
stained bands; minor components may be difficult to resolve.  The stain is useful because it does 
not appear to have a deleterious effect on the sequencing of blotted polypeptides and is therefore 
one method of choice for locating polypeptides on Western blots for blot-sequencing.  The stain 
binds strongly to nylon-based filter media but is fine for nitrocellulose and PVDF membranes.  
Incubate the membrane for up to an hour in staining solution with gentle agitation.  Rinse the 
membrane in distilled water until the background is clean.   The stain can be completely removed 
from the protein bands by continued washing.  Stain solution can be re-used up to 10 times.  
How we use it in the laboratory. Incubate the blot in Ponceau for 2-3 min to visualize the 
proteins and to determine whether the transfer was homogeneous. With a pen, mark the position 
of the molecular weight markers. The blots are then subjected to the following incubations. 
4.2. wash 3x 20 min at room temperature with TBS/0.1% Tween 20 (TBS/Tween; found in the 
big tank next to the sink near the entrance of the laboratory). 
4.3. 45-60 min at room temperature with TBS/5% powdered milk (TBS/milk). 
4.4. overnight with the primary antibody (in TBS/milk) at 4°(in a cold room). 
4.5. 3x 20 min at room temperature with TBS/Tween. 
4.6. 45 min at room temperature with TBS/milk. 
4.7. 45 min with the secondary antibody (in TBS/milk) at room temperature (if the secondary 
antibody bears a fluorochrome sensitive to light [e.g. antibodies required for the odyssey 
detection; see SOP 17], make sure that incubation is performed in a black box ). 
4.8. 3x 20 min at room temperature with TBS/tween (in the dark). 
5. Detection of the secondary antibodies on films. 
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5.1. This method should be used only for antibodies and antigens that do not generate strong 
signals. If this is not the case, detect the secondary antibodies with the BioRad Fluor-S 
imager (refer to SOP 2.0) or even better with the Odyssey apparatus (see SOP 17). 
5.2. Check that the developer has been turned on and is ready to be used. 
5.3. Prepare a cassette that should contain a fluorescent ladder (to position your film on the blot 
later on). 
5.4. Wash a glass plate thoroughly (first with soap, rinse with water and finally with ethanol). 
5.5. Prepare the ECL reagent by mixing equal volumes of solutions I and II. You need about 1 
ml for each 10 cm2 of your blot. 
5.6. Cut some Kappak plastic sheet that will be used to contain your blot during the exposure to 
films. Seal it but leave one side open. 
5.7. Take the blot with tweezers and touch some absorbing paper with one of its corner to 
remove the liquid in excess. Place the blot on the glass plate with the transferred proteins 
up. Pour the ECL reagent on the blot. Check that the whole surface is covered and wait one 
minute. 
5.8. With tweezers, transfer the blot in the Kappak bag. Remove the bubbles and seal the bag. 
Using absorbing paper, remove the liquid on the exterior of the bag. Place the bag in the 
cassette as close as possible to the fluorescent ladder. Tape the bag on one side. 
5.9. Immediately, go to the dark room with the sealed blot, the films and a cassette. Place a film 
on the blot. Close the cassette. Wait one minute. Remove the first film that you insert in the 
developer. While the first film develops, place a second one on the blot and close the 
cassette. When the first film comes out, check the intensity of the signal. If it is weak, 
expose the second film for 5-15 min. If it is too strong, develop the second film immediately 
(it will of course be too dark too) and expose a third film to 5-15 seconds. If the film has to 
be exposed for 1-2 seconds, tape it on the other side of the cassette. This will ensure that 
when you close the lids, the film will not move. Note again that if the signal is strong, you 
should not use this technique (see point 3.1). 
5.10. Keep all the films (the overexposed ones are often used to position the molecular weight 
markers). All the films should be labeled (do it immediately) with the date, the experiment 
number, the exposure time, the type of ECL used, and the experimental conditions for each 
lane. Also try (when possible) to identify the bands on your blots. 
6. Detection of the secondary antibodies with the BioRad Fluor-S imager. 
6.1. Refer to SOP 2.0. 
6.2. In this case also, the images obtained should be labeled: date, the experiment number, the 
exposure time, the type of ECL used, and the experimental conditions for each lane. Also 
try (when possible) to identify the bands on your blots. 
7. Quantitation of the ECL signal. 
7.1. In principle, quantitation should not be performed using films because the signal on films is 
not linear (you need more that one photon to active the silver grains) and saturates rapidly. 
7.2. If possible, quantitation should be performed using the BioRas Fluor-S imager. Please refer 
to SOP 2.0. 
 
8. Detection of the secondary antibodies using the Odyssey system (Licor). 
8.1. Refer to SOP 17. 
9. No signal 
9.1. Increase the incubation with the antibodies: o/n incubation with the first antibody and 2-4 
hours with the secondary antibody. Perform the incubations at 4°C. 
9.2. Reduce the “stringency” of the incubation buffer. Milk containing buffer can possibly 
quench a fraction of the antibody. The following buffers are ranked from highest to lowest 
stringency: milk-containing buffer, BSA containing-buffer, tween-containing buffer, PBS or 
Tris buffer. 
10. How to store antibodies. 
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It is possible to reuse antibodies many times and this should be done whenever the antibody is 
rare and not available commercially. The solution containing the antibody needs to contain 
0.05% azide (NaN3) and 10 mM EDTA. 
 
11. Very important: after completion of the Western blot procedure, always store the nitrocellulose 
membranes in Kappak bags at -20°C for further potential use. 
 
__________________________________________________________________________ 
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Reagents 
 
Chemicals/medium Source/Company Code/quantities 
   
JETstar maxi Genomed 20 prep (#220020) 
Isopropanol   
Glycerol   
Tris   
EDTA   
 
TE: Tris 10 mM pH 7.4, EDTA 1 mM. 
__________________________________________________________________________ 
 
Bacteria culture 
 
1. For most plasmids, inoculate 250 ml of LB with the appropriate antibiotic (see SOP 8.0) with: 
- a tip that has touched a colony on an Agar plate.  
- a few ml of a mini-prep culture 
- a chunk of a glycerol stock taken with a yellow tip 
2. Incubate o/n at 37°C in a shaker. 
3. If required, take 1 ml of the culture to prepare a glycerol stock (put this one ml in an Eppendorf tube, 
centrifuge in an Eppendorf centrifuge at 4’000 rpm for 5 min, discard the supernatant and resuspend 
the pellet in 300-500 µl of a sterile 10% glycerol solution; store at –70°C). 
 
Maxi prep 
 
1. Principle. 
The procedure employs a modified alkaline/SDS method to prepare the cleared lysate. After 
neutralization, the lysate is applied onto a JETstar column and the plasmid DNA is bound to the 
anion exchange resin. Washing the resin removes RNA and all other impurities. Afterwards, the 
purified plasmid is eluted from the column and finally concentrated by alcohol precipitation. The 
supplier says that the JETstar purified plasmid DNA is of a higher quality than 2 x CsCl purified 
plasmid DNA. The expected yield for a maxi column is between 300-500 µg of DNA. 
2. Centrifuge the cultures in 250 ml bottles at 5’000 rpm for 5-10 min at 4°C using the GSA rotor in the 
Sorvall RC-5B centrifuge. Check that the rotor is clean before and after use. Clean if necessary and 
always remove any liquid present. 
3. Place the column on the “blue cow”. Add 30 ml of solution E4 in the column and let flow by gravity. 
4. Note: RNAse must be added to solution E1 prior to its first use. Just poor the lyophilized RNAse 
powder into bottle E1 and mix. Add the sticker indicating that the RNAse has been added, the date 
and your name. Discard the supernatant. Resuspend the pellet in 10 ml of solution E1. 
5. Add 10ml of solution E2 and mix gently. Incubate 5min at room temp on a rocker (Rocker lnotech; 
shake 9, timer 5, frequency 17). 
6. Add 10 ml of solution E3 and mix immediately by inverting the bottle 5 times. Transfer to a 50 ml 
blue Falcon tube (do not use yellow Falcon tube since they are more fragile and may break during the 
centrifugation). Centrifuge at 9’000 rpm for 10 min at 20°C using the SLA 600TC rotor in the 
Sorvall RC-5B centrifuge. 
7. Poor the supernatant on the column and let flow by gravity. Wash the resin with 60 ml of solution 
E5. 
8. Place the column on a 50 ml blue Falcon tube and secure the column on the tube with tape. Add 15 
of solution E6 and let flow by gravity. 
9. Add 10.5 of isopropanol. Mix and incubate on ice for at least 1 hour (alternatively, the tube can be 
stored o/n at –20°C). 
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10. Centrifuge at 10’000 rpm for 30 min at 4°C using the SLA 600TC rotor in the Sorvall RC-5B 
centrifuge. Discard the supernatant being very careful not to loose the pellet that is not always firmly 
adherent (sometimes not at all). 
11. Add about 20 ml of 70% ethanol. Centrifuge at 10’000 rpm for 10 min at 4°C using the SLA 600TC 
rotor in the Sorvall RC-5B centrifuge. Discard the supernatant as above. Aspirate all the residual 
drops with a long white tip. 
12. Resuspend the pellet in 500 µl of TE. 
13. Measure the concentration with the spectrophotometer using a 1/100 dilution in a quartz cuvette. One 
OD at 260 nm corresponds to 50 µg/ml of DNA. The ratio between the OD at 260 nm and the OD at 
280 nm should be between 1.8 and 2.0. 
Write down the concentration of the maxi prep in the plasmid files as well as on the tube. 
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Materials and reagents 
1. coverslips keep in ethanol 100% 
Materials and reagents Source/Company Code/quantities 
   
PBS 10 X 
 
? ? 
0.2% TX-100 in PBS 
 
 
 
 
 
 
PBS 1X, 3% 
paraformaldehyde, 
3% sucrose 
  
Gelatin Fluka 48722 (500 g) 
Mounting medium   
Antibody   
   
 
1.1. Preparation of a PBS/0.1% gelatin solution (500 ml). 
Add 0.5 g gelatin and 50 ml PBS 10X to 450 ml ddH2O in a glass bottle. Autoclave and 
store at 4°C. 
 
2. List of antibodies  
 
Name of 
Ab 
Name of 
epitope or 
antigen 
Origin of 
Ab 
Source 
 
Company or 
source 
Dilution 
      
 
__________________________________________________________________________ 
Procedure 
 
Preparation of coverslips  
 
Growing cells on coverslips 
1. In a sterile hood, take a coverslip from the ethanol bottle with tweezers. Set fire to the ethanol by 
passing quickly the coverslip over the flame. When all the ethanol has burnt and evaporated, 
place it in the appropriate culture plastic-ware. If required, coat the wells and the coverslips with 
PBS/0.1% gelatin for at least 10 minutes. Remove the PBS/gelatin if present and add the cells to 
the wells. Transfect or infect the cells if required. 
 
Immunocytochemistry 
1. Fill the required number of wells of 6-well plates with ~3ml PBS 1X (these 6-well plates can be 
used over and over). With tweezers, transfer the coverslips to the 6-well plates (face up). This 
can be performed under a sterile hood with sterile devices if the rest of the cells (i.e. cells not on 
the coverslips) have to be kept in culture. 
2. After this step, the procedure can be continued on the bench. Use ~20°C solutions (solutions that 
have been kept at room temperature). 
3. Aspirate the PBS 1X and put gently 3ml of PBS 1X, 2% paraformaldehyde, 3% sucrose. 
Incubate 15 min in the dark (fixation step). 
4. Wash very carefully with 3 ml PBS 1X. 
5. Add very carefully 3ml 0.2% TX-100 in PBS 1X. Incubate the coverslips 10 min in the dark. 
(permeabilization of the membrane) 
6. Wash very carefully with 3 ml PBS 1X. 
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7. Put 3 ml of sterile filtered serum-containing medium for 15 min in the dark (old sera can be used; 
filtrate the medium through 0.2 µm Millipore filter). These media are kept in the cold room. Take 
what is needed for the experiment (do not forget to include volumes used to dilute the antibodies) 
under a sterile hood and work according to cell culture standards. 
8. Place some parafilm on a clean portion of the bench. Stretch the parafilm and fix it on the table 
with tape. 
9. Dilute the first antibody in filtered medium and place 50 µl drops on the parafilm (1 drop per 
coverslip). 
10. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with 
the edge of the coverslip, and place the coverslip on the drop, face down. 
11. Cover the coverslips with a lid (typically the top part of a foam box used for the shipping of 
frozen biological goods ) with paper tapped on the interior side that must be moistened with 
water to reduce the extent of evaporation of the medium containing the antibodies. Incubate one 
hour. 
12. Prepare a small becher containing PBS 1X. 
13. Place 50 µl drops containing the second antibody (or any kind of labeling reagent) on a stretched 
parafilm (see #8-9). 
14. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with 
the edge of the coverslip, hold the coverslip ~5 seconds in the PBS-containing becher, remove 
the excess liquid and place the coverslip on the drop, face down. Cover with a lid as described in 
#11 and incubate for a further hour. 
15. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with 
the edge of the coverslip and place the coverslips face-up into the 6-well plate still filled with the 
filtered serum-containing medium. 
16. Perform 6 incubations with PBS 1X in the dark. The incubations should last at least 20 min 
(preferably 30 min). If the coverslips float up (which happens especially during the last washes), 
push them to the bottom of the wells with the tweezers. 
17. Clean the required number of slides to mount the coverslips. 
18. For each coverslip, place 2 µl of mounting medium on the slide (up to four coverslips can be 
mounted per slide). 
19. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with 
the edge of the coverslip and place the coverslips face-down onto the drops of mounting medium. 
20. With a long white tip connected to the vaccum, remove the excess of mounting medium trying 
not to move the coverslips. 
21. Put some nail polish around the coverslips. 
22. Let the nail polish dry a few hours (typically o/n). 
23. Gently remove the dried PBS on the coverslips with a wet piece of Kleenex tissue. 
24. The coverslips can now be analyzed with the appropriate imaging system. 
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IMPORTANT NOTE 
The viral supernatants produced by these methods might, depending upon your retroviral insert, 
contain potentially hazardous recombinant virus. The user of these systems must exercise due 
caution in the production, use and storage of recombinant retroviral virions, especially those with 
amphotropic and polytropic host ranges. This consideration should be applied to all genes expressed 
as amphotropic and polytropic pseudotyped retroviral vectors. Appropriate guidelines should be 
followed in the use of these recombinant retrovirus production systems. 
The user is strongly advised NOT to create retroviruses capable of expressing known oncogenes in 
amphotropic or polytropic host range viruses. 
 
According to the Swiss Legislation all the manipulations done using lentiviruses, must be 
performed in a P2 security Laboratory. 
For details and authorization for using the P2 Lab, contact Sylvain Lengacher at the Institute of 
Physiology (tel. 021 692 55 46, email: Sylvain.Lengacher@unil.ch) 
 
For some additional information concerning the Lentiviral Systems you can check the following 
websites. 
Garry Nolan’s Lab website at Stanford University: http://www.stanford.edu/group/nolan/ 
Didier Trono’s Lab website at Geneva University:  http://www.tronolab.com/ 
_________________________________________________________________________________ 
Reagents. 
Hexadimethrine bromide (Polybrene), Fluka (Sigma Cat. N° 52495) 
Sucrose, Fluka (Sigma Cat. N° 84100) 
Paraformaldehyde 95 %, (Sigma Cat. N° 441244) 
Penicillin-Streptomycin Glutamine 100x solution, (GibcoBRL Cat N° 10378-016) 
0.45 µm filters, Millex-HN, 0.45um, 25mm, stérile, 50/PK (Milian Cat N° SLHN025NS) 
0.22 µm filters, Millex-GN, 0.22um, 25mm, stérile, 50/PK (Milian Cat N° SLGN025NS) 
Chloroquine (Sigma Cat. N°C6628). 
Laminin, mouse (1 mg) (BD Bioscience Cat. N° 354232) 
Poly-D-Lysine (20 mg) (BD Bioscience Cat. N° 354210) 
Biocidal ZF (1 l) (WAK Chemie Cat N° WAK-ZF-1) 
 
Solutions. 
 
1X Phosphate Buffered Saline (PBS) 
NaCl,  8 g 
KCl,  0.2 g 
Na2PO4,  1.44 g  
KH2PO4  0.24 g  
H2Odd  800ml  
Adjust pH to 7.4 with HCl. 
Adjust volume to 1 liter with additional distilled H2O. Sterilize by autoclaving. 
 
Tris-EDTA (TE) buffer. (10 mM Tris; 1 mM EDTA; pH 8.0)  
1 M Tris pH 8.0  1 ml   
0.5 M EDTA pH 8.0  0.2 ml   
H2Odd 98.8 ml   
Autoclave 
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Polybrene 5 mg/ml (10 ml). 
Dissolve 5 mg of Polybrene in 10 ml of PBS. Filter through a 0.22 µM filter, aliquot in eppendorf 
tubes (1 ml per tube) and store either at 4°C or at -20°C. 
 
Chloroquine 25 mM (50 ml). 
Dissolve 399.8 mg of Chloroquine in 50 ml of PBS. Filter through a 0.22 µM filter, aliquot in 15 ml 
falcon tubes (10 ml per tube) and store at -20°C. 
 
Sodium Acetate 3 M pH 5.2 (100 ml). 
To 24.6 gr of sodium acetate (Sigma Cat. N° S-2889), add 90 ml of nanopure water. Adjust the pH to 
5.2 (with glacial acetic acid) and complete to 100 ml. 
 
Fixation Solution (2% Paraformaldehyde 3% Sucrose). 
a. Weigh 0.2 gr paraformaldehyde in a 15 ml tube. 
b. Add 6 ml PBS. 
c. Warm up to 60˚C and vortex. 
d. Add drops of 0.5 M NaOH, warm up to 60° C and vortex until it dissolves. 
e. Add 0.3 gr of Sucrose and make up the volume to 10 ml with PBS. 
f. Make sure the final solution is neutral. 
 
Procedure 
Note: for details on the transfection protocol, refer to SOP001 Transfection (calcium-phosphate). 
Day 0. 
1. Prepare five 10 cm gelatinized Petri dishes containing 2 - 2.5x106 HEK293T cells in 10 ml 
medium. 
Gelatinization of the dishes. 
Place between 2 to 5 ml of PBS/0.1% gelatin in the dish [See SOP001] (tilt the plate to cover the 
entire surface with the solution). Wait at least 10 min. Just before adding the cells to the plates, 
aspirate the PBS/0.1% gelatin (do not allow the plates to dry). 
Day 1. 
2. Prewarm all the solutions in a 37°C water bath (at least 20 min). In case the buffer is thawed, mix 
very well before using. 
3. Add 25 µM chloroquine (10 µl of the 25 mM solution) to the cell culture medium (not necessary 
to change the medium). Place the plates back in the incubator for at least 10 min. 
The addition of chloroquine to the medium appears to increase retroviral titer by approximately two 
fold. This effect is presumably due to the lysosomal neutralizing activity of the chloroquine (3). It is 
extremely important that the length of chloroquine treatment does not exceed 12 hours. Longer 
periods of chloroquine treatment have a toxic effect on the cells causing a decrease in retroviral 
titers. 
4. In a 15 ml Falcon tube prepare the following master mix: 
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 Volume or quantities 
H2O  
pCMV delta R8.91 
pMD.G 
Lentiviral vector (e.g. 
Prom.lti) encoding the gene of 
interest 
CaCl2 
2xHepes  
Variable 
37,5 µg 
12,5 µg 
50 µg 
 
250 µl 
2500 µl 
FINAL VOLUME 5 ml 
All the plasmid should be prepared using Qiagen or Genomed Maxiprep kits and ethanol 
precipitated. In case the yield of the plasmid is not very high it should be purified using the CsCl 
purification method. 
• Ethanol Precipitation: 
a- Carefully calculate the volume of your DNA solution. 
b- Add 1/10 volume of 3 M Sodium Acetate pH 5.2, mix well. 
c- Add 2 volumes of cold absolute ethanol. 
d- Keep at -20° C for at least 1 hour. 
e- Centrifuge 10’ at maximum speed. 
f- Discard supernatant and wash pellet with ethanol 70 % three times. 
g- Air dry and resuspend in TE. 
h- Measure DNA concentration. 
5. Mix well, by passing 5 times the solution through a 5 ml pipette.  
6. Exactly 60 seconds after mixing the 2xHepes with the CaCl2-DNA mixture, add 1 ml precipitate 
per plate. 
7. Incubate for 6-8 hours in an incubator (37°C - 5% CO2). 
8. Remove medium, wash once with PBS and put fresh medium containing penicillin and 
streptomycin to avoid contamination (the DNA used for the transfection is generally not sterile!). 
9. 48 hours after the transfection, collect the supernatant of the plates in a 50 ml Falcon Tube. 
10. Centrifuge for 5’ at 1500 rpm (~400 g) at 4°C to pellet the detached cells (ALC PK 130 
centrifuge, rotor N° T535). 
11. Filter the cleared virus-containing supernatant through a 0.45 µm filter, wrapping everything in a 
towel humidified with biocidal to avoid aerosols. 
12. Once the virus is filtered, aliquot in 15 ml falcon tubes. 
Note: The size of the aliquots may change according the use you will give to your virus.  
13. Keep the virus at -80°C. 
Freezing does not appear to cause more than a 2-fold drop in titer, as long as the cells do not 
undergo more than one freeze/thaw cycle. If the cells undergo more than one freeze/thaw cycle, there 
is a significant drop in retroviral titer. 
14. If the virus encodes for a protein that can be detected, calculate functional titer by 
immunocytochemistry (See SOP011 Immunocytochemistry), as detailed below [for siRNA 
encoding lentiviruses you may calculate your functional titer by monitoring by western blot the 
conditions that lead to the best decrease of the targeted proteins, (See SOP006.1 Western Blot)]. 
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1. Laminin-Polylysin coating 
PolyLysine.  
Comes as 20 mg/vial. Add sterile H2O to the vial to a final volume of 1 ml to make a 1 mg/ml stock 
solution (in a 50 ml falcon tube). Make 1 ml (=1 mg) aliquots. Store at -20 C. 
Laminin. 
Comes as 1 mg/vial. Add sterile H2O to the vial to a final volume of 1 ml to make a 1 mg/ml stock 
solution. Make 100 µl (=100 µg) aliquots. Store at -70 C. 
Coating Coverslips. 
1. Thaw 1 tube of polylysine and laminin solution. 
2. Add laminin, poly-lysine to 25 ml of sterile H2O. 
3. Use 50 µl solution for each coverslips. Place at 37° C for 2 hrs. 
4. Rinse 3x with PBS, and use to plate cells. 
 
2. Plate the appropriate number of cells (according to your cells type) in six-well dishes, with 
two laminin-coated coverslips in each well. 
 
Cells 
Number per 
well (6 well-
plates) 
Medium Coating 
GAP +/+ and 
derived cell 
lines 
3-5.104 DMEM; 10% NBCS Polylysin /Laminin  
HEK 293 and 
derived cell 
lines 
35.104 DMEM; 10% NBCS Polylysin /Laminin  
β-Tc-Tet and 
derived cell 
lines 
105 
DMEM (without L-Glu); 
15% Horse Serum (Heat 
decomplemented); 2,5% 
FCS; 2 mM L-Glu; 10 mM 
Hepes pH 8; 1 mM Na-
Pyruvate 
Polylysin 
/Laminin  
3. Incubate cells at 37°C, for 12-18 hours.  
Important: infect cells when they are not more than 50% confluent. 
4. The following day, thaw the frozen virus at 37°C (shake often) and once nearly completely 
thawed, keep on ice. The virus should stay at 0°C all the time. 
5. Add various amounts of viruses according to the table below, add 2 µl of a 5 mg/ml 
polybrene stock solution and complete with fresh medium to 3 ml. 
Cell # 0 ml 0.25 ml 
0.5 ml 1 ml 2 ml 
6. Immediately thereafter, seal the plates with parafilm and centrifuge them 45' at 2’500 rpm 
(~800 g) (ALC PK 130 centrifuge, rotor N° T537). 
7. Incubate overnight in incubator (37°C - 5% CO2). 
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8. Change medium after 24 hours. 
9. Remove medium 72 hs after infection and rinse once with 2 ml of PBS. 
10. Fix cells by adding 1 ml of PBS-2% paraformaldehyde-3% Sucrose, for 15 minutes. 
11. The following immunocytochemistry steps can be performed on the bench (See SOP011). 
12. Knowing the number of cells at the moment of infection and the smallest volume that leads 
to expression of the gene of interest in ~100% of the cells, you can estimate the number of 
infective particles per ml. 
_________________________________________________________________________________
_________ 
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Apparatus 
 
Hybridization oven. Biometra OV 3 – C Lab 
 Agarose gel electrophoresis system. 
 
Materials and reagents 
 
1. Hybond N+ membrane (30 cm × 3 m) 1 roll. (Amersham Biosciences Cat. N° RPN303B). 
2. Chromatography paper 3MM Chr (46x57 cm) 100 sheets. (Whatman Cat. N° 3030917) 
3. Random primed labeling kit. (Roche Applied Science Cat. N° 1004760) 
4. High Pure PCR purification kit (50 purifications). (Roche Applied Science Cat. N° 1732668) 
5. [α-32P]-dCTP 250 µCi. (CHIMBAR Ref N° R00031). 
6. Hybridization bottle, 260 × 40 mm (Amersham Biosciences Cat. N° RPN2516) 
7. Hybridization bottle, 170 × 40 mm (Amersham Biosciences Cat. N° RPN2517) 
8. JETSORB Gel Extraction Kit, 150 Preps (Genomed Cat N° 110150) 
 
  
Materials and reagents Source/Compa
ny 
Code/quantities 
NaCl Fluka IBCM Stock /1 kg 
Ammonium Acetate 7.5 M Sigma A-2706 / 100 ml 
UltraPure™ Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1, v/v) 
Gibco 15593-031 / 100 
ml 
SDS CHIMBAR C00495 / 4 kg 
Proteinase K Roche 3 115 828 / 5 ml 
Sodium phosphate dibasic Sigma 500 gr 
Tris CHIMBAR C00511 / 4 kg 
EDTA Fluka 03620 / 1 kg 
Phosphoric Acid Acros 201140010 / 1 L 
Albumin, Bovine Sigma A7906 / 100 gr 
Sodium Citrate Sigma C-8532 / 5 kg 
 
Digestion Buffer. (100 mM NaCl ; 10 mM Tris-HCl pH 8; 25 mM EDTA pH 8; 0.5 % SDS; 0.1 
mg/ml Proteinase K) 
5 M NaCl 200 µl 
100 mM Tris-HCl pH 8  1 ml 
0.5 M EDTA pH 8  500 µl 
20 % SDS 250 µl 
Proteinase K (16-20 mg/ml)  5.5 µl 
H2Odd up to  10 ml 
 
Hybridization Solution. (0.5 M Sodium Phosphate pH 7.2; 7% SDS, 1mM EDTA and 1% BSA).  
1 M Phosphate Buffer pH 7.2  150 ml 
SDS 20 %  105 ml  
0.5 M EDTA pH 8  0.6 ml 
BSA  3 gr 
H2Odd up to  300 ml 
 
Neutralizing solution. (1,5 M NaCl; 0.5 M Tris-HCl 7,2 and 1 mM EDTA pH 8) 
5 M NaCl  300 ml 
1 M Tris-HCl pH 7.2  500 ml 
0.5 M EDTA pH 8  2 ml  
H2Odd up to  1000 ml 
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Washing Solution I (40 mM Sodium Phosphate pH 7.2; 1% SDS,; 5 mM EDTA and 0.5 % BSA) 
1 M Phosphate Buffer pH 7.2  40 ml 
20% SDS  50 ml 
0.5 M EDTA pH 8  10 ml 
BSA  5 gr 
H2Odd up to  1000 ml 
20x SSC. (3 M Sodium Chloride; 0.3 M Sodium Citrate, pH 7.0) 
Weight 175.5 gr of NaCl and 88.2 gr of Sodium Citrate, complete to 800 ml with nanopure water, 
adjust the pH with NaOH and once the pH adjusted complete to 1000 ml with nanopure water. 
 
NaHPO41 M pH 7.2. 
Weight 71 gr of Na2HPO4 and add 4 ml of 85% H3PO4. Complete with water and check pH. Other 
phosphate buffers can be prepared from this stock solution. 
 
EDTA 0.5 M pH 8 (1 liter). 
Weight 186.1g disodium EDTA-2H2O and add 800 ml distilled water. Stir vigorously (it takes 
forever! heat OR add NaOH to help dissolution, but in this case do not heat as NaOH is volatile. 
Adjust the pH to 8.0 with NaOH 10 M and later 1 M. 
 
Tris-EDTA (TE) buffer. (10 mM Tris; 1 mM EDTA; pH 8.0)  
1 M Tris pH 8.0  1 ml   
0.5 M EDTA pH 8.0  0.2 ml   
H2Odd 98.8 ml   
Autoclave 
 
__________________________________________________________________________ 
Procedure  
 
1. General remarks. 
1.1. Always test more than one probe!!!!!!!!!. 
 
2. Genomic DNA purification (Current Protocols) 
2.1. Trypsinize and collect cells, centrifuge 10’ at 500xg and discard supernatant. 
2.2. Resuspend cells with 1 to 10 ml of ice-cold PBS. Centrifuge 5’ at 500xg and discard 
supernatant. Repeat this resuspension and centrifugation step. 
2.3. Resuspend cells in 1 volume of digestion buffer. (For <3x 107 cells use 0.3 ml digestion 
buffer. For larger number of cells use 1 ml digestion buffer/108 cells. 
2.4. Incubate the samples with shaking at 50° C for 12 to 18 hr. 
2.5. Thoroughly extract the samples with an equal volume of phenol/chloroform/isoamyl alcohol 
(24.5:24.5:1). 
2.6. Centrifuge 10’ at 1700xg in a swinging bucket rotor (Sigma centrifuge 4K15, rotor N° 
11’140). 
2.7. If the phases are not well separated, add another volume of digestion buffer, omitting 
Proteinase K, and repeat the centrifugation. 
2.8. Transfer the aqueous (top) layer to a new tube and add ½ volume of 7.5 M ammonium 
acetate and 2 (original) volumes of 100% ethanol. Centrifuge 2’ at 1700 x g. 
2.9. Rinse the pellet with 70% ethanol, decant ethanol and air dry the pellet. 
2.10. Resuspend DNA in TE buffer until dissolved. DNA may be shaken gently at 
room temperature or at 65° C for several hours to facilitate solubilization. 
2.11. Measure DNA concentration and quality. 
The concentration of DNA is read by measuring the absorbance of a sample at 260 nm on a 
spectrophotometer. The OD260/OD280 ratio can be determined in order to assess the purity of the 
sample. If this ratio is 1.8 - 2.0, the absorption is probably due to nucleic acids. A ratio less than 1.8 
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indicates that there may be proteins and/or other UV absorbers in the sample, in which cases it is 
advisable to re-precipitate the DNA. A ratio higher than 2.0 indicates that the samples may be 
contaminated with chloroform or phenol and should be re-precipitated with ethanol. 
DNA measures are estimated from the 260 nm readings. The values are in OD (optical density units) 
where 1 OD = 50 ng/µl. Therefore if you get a value of 0.2 OD, your concentration is 50*0.2 = 10 
ng/µl. If you have made a dilution of your DNA you need to multiply again for the dilution factor.  
For example, if you have used 2 µl of your DNA sample in 98 µl of water (dilution 1/50) you need to 
multiply the previous value by your dilution factor. Therefore a reading of 260 nm = 0.2 OD 
represents 10*50 = 500 ng/µl in your original DNA sample. In summary, with a 1/50 dilution, 
multiplication of the 260 nm OD by 2500 (50*50) will provide the final concentration. 
 
3. Digestion. 
3.1. Digest your genomic DNA in the following conditions. 
DNA   15 - 20 µg 
Enzyme   10 U  
Buffer 10x  4 µl 
H2Odd  up to 40 µl 
 Perform the digestion overnight at 37° C, preferentially in a bacterial incubator, to avoid 
evaporation. 
3.2. Once the digestion is finished, check if the digestion was complete by taking 2 µl of the 
digestion, mixed with 4 µl of LB and loaded in a gel. Once the blue is in the middle of the 
gel, check the gel in the transiluminator and see whether there is a smear (indicating that the 
digestion indeed occurred).  
If the digestion is complete continue with the following steps. 
  
4. Transfer 
4.1. After fractionating the DNA by gel electrophoresis, use a razor blade to cut off a small 
triangular piece from the bottom right-hand corner of the gel for orientation purposes. 
4.2. Denature DNA as follows: 
 - 10’ in 0.25 N HCl or until loading gel becomes yellow. (Depurination) 
 - 30’ in 0.4 M NaOH. (Denaturation) 
 - 20’ in 1.5 M NaCl; 0.5 M Tris-HCl pH 7.2; 1 mM EDTA pH 8. 
(Neutralization) 
 - 5' in 20X SSC. 
4.3. While denaturing DNA, using gloves and a fresh scalpel, cut a piece of nylon membrane ~1 
mm larger than the gel in each dimension. Also cut eight sheets of thick blotting paper 
(Whatman3MM paper) to the same size as the membrane. 
4.4. Float the membrane on the surface of a dish of H2Odd until it wets completely from 
beneath, then immerse the membrane in 2x SSC and finally into the transfer buffer for at 
least 5 minutes. Using a clear scalpel blade cut a corner of the membrane to match the 
corner cut from the gel. 
4.5. Assembly of the Transfer Apparatus. 
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4.6. Place a piece of Whatman paper on a sheet of Plexiglas or glass plate to form a support that 
is longer and wider than the gel. The ends of the paper should drape over the edges of the 
plate. Place the support inside a baking dish. 
4.7. Fill the baking dish with the transfer buffer. Once the Whatman paper is thoroughly wet, 
smooth out all air bubbles. Add 4 sheets of wet Whatman paper, and smooth out all air 
bubbles. 
4.8. Place the gel upside-down on the support so that it is centered on the wet blotting paper. 
4.9. Wet the gel with transfer buffer. Surround gel with plastic wrap or parafilm to prevent the 
paper towels to come in contact with the wet paper below the gel.  
4.10. Place the wet membrane so that the cut corners are aligned. Try to avoid the 
formation of bubbles between the gel and the membrane. 
4.11. Wet two of the Whatman papers in the transfer buffer and place them on top 
of the wet membrane. Roll a pipette across the surface of the membrane to smooth away any 
air bubbles. 
4.12. Place the dry Whatman papers over the wet Whatman paper, and eliminate 
bubbles as before. 
4.13. Cut or fold a stack of paper towels (5-8 cm high) just smaller than the 
blotting papers. Put a glass plate on top of the stack and weigh it down with a 400-g weight. 
Prevent evaporation of the transfer solution by sealing with plastic wrap or parafilm on 
either end of the tray. 
 
 
 
4.14. Transfer overnight. 
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4.15. Next day, peel the membrane. Before peeling the membrane indicate the positions of the 
wells in the membrane making small holes in the membrane with a needle. 
4.16. Wash the filter/membrane briefly in 2 x SSC. 
4.17. Air dry (approximately 30’). 
4.18. Fix the DNA to the membrane by crosslink (Autocrosslink 1200 J, using the Stratalinker® 
UV Crosslinker from Stratagene, located in Romano Regazzi’s Lab). Any membrane not 
used immediately in hybridization reactions should be thoroughly dried, wrapped loosely in 
aluminium foil or blotting paper, and stored at room temperature, preferably under vacuum. 
5. Probe labeling 
5.1. Add to 25 ng template DNA (linear) sterile double distilled water to a final volume of 9 µl 
in an eppendorf microfuge tube. 
Template DNA can be obtained from a PCR or the digestion of a plasmid. In both cases, the band 
should be purified from the gel using the JETSORB Gel Extraction Kit from Genomed. 
Protocol: 
1. Solubilization of agarose. 
Excise the agarose gel slice, determine its weight and transfer the slice into a suitable 
tube. For each 100 mg gel slice add the following kit components: 
- 300 µl buffer A1 
- 10µl JETSORB suspension (Before use, resuspend JETSORB carefully by vortexing) 
2. DNA Binding 
Vortex and incubate the assay at 50°C for 15 min. Mix every 3 min during incubation. 
After this, centrifuge (30 sec / ³10,000 g) and remove the supernatant completely with a 
pipette. 
3. High Salt Wash 
Wash (resuspend) the pellet once with 300 µl of buffer A1. Centrifuge as before to 
recover JETSORB and remove the supernatant with a pipette. Resuspend the pellet by 
vortexing and/or flicking the tube. 
Vortexing is only recommended for DNA fragments up to 5 kb. 
4. Low Salt Wash 
Wash (resuspend) the pellet with 300 µl of reconstituted buffer A2. Centrifuge as before 
and remove the supernatant with a pipette. Repeat step 4! 
5. JETSORB Drying 
Dry the JETSORB pellet by air or under vacuum. 
Comments: Before DNA elution, the pellet must be free of ethanol. The pellet turns 
snow white when it is completely dry. 
6. DNA Elution 
Add 20 µl TE buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8.0) or water, resuspend the 
pellet as before and incubate for 5 min at 50°C. Flick the tube once during incubation. 
Centrifuge as before and transfer the supernatant into a new tube. 
5.2. Denature the DNA by heating in a boiling water bath for 10 min at 95°C and chilling 
quickly in an ice/water bath. Note: Complete denaturation is essential for efficient labelling 
5.3. Add the following to the freshly denatured probe on ice: 
 
Reagent Volume 
dNTPs Stock Mix 3 µl 
Reaction mixture (vial 6) 2 µl 
[α-32P]dCTP, 3000 Ci/ 
mmol,  
5 µl 
Klenow enzyme (vial 7) 1 µl 
 
• Incubate at 37°C for 30 min. 
5.4. Stop the reaction by adding 2 µl 0.2 M EDTA (pH 8.0) and/or by heating to 65 °C for 10 
min. 
Note: Longer incubation can increase the yield of labelled DNA. 
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6. Hybridization 
6.1. Put the membrane in the roller bottle and add 10 ml the hybridization solution for 1 small 
bottle (or 20 ml for a big bottle), pre-warmed at 65° C. 
6.2. Incubate at least 30’ at 65° C in the oven. 
6.3. Denature double stranded probes by heating the probe for 5’ at 100° C (in a thermal block or 
in boiling water) and chill rapidly on ice water. Add the probe. 
6.4. Incubate O/N at 65° C. 
6.5. Wash the membrane first with a few ml of Washing Solution, to eliminate the bulk 
radioactivity. 
6.6. Wash twice for 30' at the hybridization temperature with half filled bottle with Washing 
Solution (pre-warm the solutions) 
6.7. After the last wash, briefly wash the membrane in tap water, to eliminate the washing 
solution. 
6.8. Remove most of the liquid from the membrane by placing it on a pad of paper towels. Place 
the damp membrane on a sheet of Saran Wrap. 
6.9. Cover the membrane with a sheet of Saran Wrap, and expose the membrane to X-ray film 
for 16-24 hs at -70° C with an intensifying screen to obtain an auto radiographic image. Put 
at least two films, develop the first one, one or two days after, and keep one in case you 
need to expose longer. 
 
